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General introductionChapter 1
The leading title of this thesis may suggest that only the fittest of individuals diagnosed 
with colorectal cancer can survive this disease, in analogy with the theory of ‘natural 
selection’ proposed by Charles Darwin.1 However, the FI-test in the title refers to the 
Fecal Immunochemical Test (FIT), a stool test used in Colorectal Cancer (CRC) screening 
for tracing malignant or pre-malignant lesions in the large intestine of humans. In this 
thesis, the performance of FIT is investigated. 
In individuals diagnosed with CRC, the primary predictor of survival is the stage of disease 
at time of diagnosis.2 Asymptomatic patients, who seem to be in the best physical shape 
and thereby “the fittest” according to Darwin, can nevertheless suffer from CRC at an 
advanced stage and consequently their survival rates are only modest. 
Given the natural course of disease of CRC, with symptoms such as abdominal pain 
or hematochezia typically signaling the presence of advanced disease, screening the 
asymptomatic population is the only realistic approach to influencing mortality. 
This is one of the main arguments for screening asymptomatic individuals by means 
of mass screening. More than 50 years ago the World Health Organization defined 
screening criteria to direct the selection of conditions suitable for mass screening.3 In 
their manuscript the authors describe the main requirements for a successful screening 
program. One of the main criteria is that the targeted condition poses an important 
health problem. 
Colorectal cancer (CRC) is one of the most common cancers worldwide and thereby 
forms a major health care problem. In the USA, CRC is the third leading cause of cancer 
death and in the Netherlands CRC ranks second in cancer related deaths among women 
and third amongst men.4,5 In addition, due to the aging population the incidence of CRC 
is expected to rise up to 14,000 cases a year in the Netherlands in 2015.6
A second requirement for a successful screening program as defined by the WHO, is 
that a pre-malignant stage of the disease exists and that appropriate treatment available. 
As previously mentioned, CRC can remain asymptomatic for a long period of time. 
The chance of survival, however, decreases with an increasing stage of disease at the 
time of diagnosis. Secondary prevention, which is defined as detection and treatment 
of a disease which has yet to become symptomatic, aims to diagnose and treat existing 
disease in its early stages before it results in significant morbidity. Its high prevalence 
and natural history make CRC a prime candidate for secondary prevention by means 
of population screening. 
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Another main requirement for a successful screening program is the availability of 
a reliable test or examination to detect the condition. A screening test discriminates 
individuals who probably have a disease from those who probably have not. For mass 
screening, the methods available are either structural  examinations or fecal tests.7 The 
structural examinations are radiologic exams like double-contrast barium enema, CT-
colonography or endoscopic examinations, e.g. sigmoidoscopy and colonoscopy. 
Colonoscopy enables the direct visualization of the entire colon and is currently considered 
the gold standard for detecting colorectal cancer. Furthermore, it is the main therapeutic 
tool to disrupt the progression of precancerous polyps to cancer by polypectomy.8 
However, colonoscopy can be quite troublesome and uncomfortable for patients and there 
is an inherent risk for complications.9 Using the gold standard colonoscopy for screening, 
would lead to a large additional burden of endoscopic work. The already overstretched 
endoscopic capacity in several countries, hampers a colonoscopy screening program at 
such a large scale.6,10 Therefore, a preselecting screening tool is needed to decrease the 
total number of colonoscopies performed in a colorectal cancer screening program and 
for this purpose, fecal tests can be used. Moreover, formal cost effectiveness analyses 
favor screening with FIT over colonoscopy.
The fecal tests can be divided in fecal occult blood tests (FOBTs) and biomarker based 
tests like stool DNA tests. There are two types of FOBT, namely the guaiac based test, 
or g-FOBT, and the Fecal Immunochemical Test, or FIT. In the present thesis, the test 
performance of FIT will be described and its applicability discussed.
AIMS AND OUTLINE
The aim of this thesis was to assess test characteristics of fecal occult blood tests for the 
detection of precursor lesions of CRC, thereby contributing to the basis of an organized 
population screening program for CRC. To this end, a large, multicenter, cohort of 
colonoscopy controlled individuals was investigated. Test characteristics of FIT were 
compared to the gold standard colonoscopy. In this cohort several research questions 
could be addressed concerning test performance of FIT. 
The chapters of this thesis address three main themes. The first theme is comparing 
FIT to g-FOBT, which was the standard test in colorectal cancer screening, but in the 
mean time has become outdated. The second theme deals with different strategies for 
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optimization of the diagnostic accuracy of FIT. In addition, several factors that influence 
the test performance of FIT have been identified. The third theme focuses on the future; 
FIT is combined with a DNA methylation marker. Biomarkers will certainly play a role 
in the future of fecal tests in the detection of colorectal cancer, and the added value of a 
methylation marker to FIT is assessed.
“The past”
Guaiac-based fecal occult blood tests (g-FOBTs) were already proposed for use in 
colorectal cancer screening in the early 1960s.11 Blood, shed into the colonic lumen by 
colorectal adenomas and carcinomas, yields a positive g-FOBT due to the peroxidase-like 
activity of heme in human stool.12 
Historically stool screening has always relied on the detection of occult blood, which is 
non-specific and has a limited sensitivity as a marker for colonic neoplasia. Consequently, 
many physicians and their patients have been hesitant to embrace the use of FOBTs, and 
a relatively small minority of adults adheres regularly to this type of stool screening.13 
Nevertheless, with this test formal evidence has been generated that occult blood testing 
can reduce death rates from CRC.14-16 
In chapter 2 sensitivity and specificity is assessed of g-FOBT (Hemoccult-II©) and FIT 
(OC-sensor©) for adenomas and CRC in eligible subjects who underwent complete 
colonoscopy. At the time of publication, this study was one of the few studies that head 
to head evaluated FIT and g-FOBT, with all individuals performing both tests at the same 
time. In addition, because all individuals underwent colonoscopy, specificity could be 
calculated directly. 
The present: pitfalls in use of FIT and improvement strategies
One of the major advantages of FIT is its non-dichotomous but quantitative outcome. A 
cut-off value can be set to define the threshold for test positivity. By adjusting this cut-off 
value, the positivity rate can be influenced. When applied in a CRC screening program, 
a lower cut-off level for FIT will result in more screenees being referred for colonoscopy, 
and due to lower specificity, a higher number of futile colonoscopies. Higher FIT cut-off 
levels will decrease the strain on colonoscopy resources, but might also leave more curable 
CRCs undetected. In chapter 3 the influence of using higher cut-off values for a FIT on 
the detection rates of screen-relevant neoplasia was assessed. 
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By lowering the cut-off value of FIT, sensitivity is increased at the cost of specificity. One 
approach for improving the sensitivity of FIT based screening could be to increase the 
number of samples tested, which is common practice for g-FOBTs. Chapter 4 focuses 
on repeated FIT sampling as another strategy for improving the test sensitivity of FIT 
for detection of CRC and its precursors. Test positivity of double FIT sampling was 
evaluated for three different strategies. First “one of two FITs positive” when at least one 
out of two measurements exceeded the cut-off value. Second, “both FITs positive” when 
both measurements exceeded the cut-off value, and third “the mean of two FITs positive” 
when the geometric mean of two FITs exceeded the cut-off value. These strategies were 
evaluated at fixed specificities.
In chapter 5 the focus lies on false positive FITs. In population-based screening with 
FIT, participants with a positive test result are referred for colonoscopy. In about half of 
all screenees with a positive FIT result, no advanced neoplasia is found at colonoscopy. 
These false positives could lead to unnecessary colonoscopy-related complications, 
pointless strain on endoscopic resources, psychological stress for the screenee, and 
diminished trust in the screening program. Therefore, the number of false positive results 
should be kept as low as possible. In this chapter, the contribution of hemorrhoids to 
the frequency of false positive FITs was determined. In a univariate unadjusted analysis, 
subjects with hemorrhoids as single abnormality were compared with subjects without 
any abnormalities. 
Recent literature suggests that FITs have a higher sensitivity and lower specificity for 
advanced colorectal neoplasia in males compared to females.17 The uptake of a screening 
program is not solely dependent on test performance of FIT, but a true difference in FIT 
characteristics between males and females could lead to disparities in the expected benefit 
of CRC screening between both sexes. Gender disparities could necessitate more tailored 
screening, i.e. sex-specific screening guidelines. In chapter 6 potential inequalities in test 
performance of FIT between sexes are assessed. The aim of this chapter was to compare 
males and females with respect to the sensitivity and specificity of FIT, at different cut-off 
values. Outcome measures were CRC and advanced adenomas.
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“The future”
The future is the final theme of this thesis, and in chapter 7 a potential option for im-
provement of test performance of FIT is described. As mentioned previously, FIT detects 
hemoglobin, which is a non-specific, blood derived marker, leaked from colonic neoplastic 
lesions into the stool. The products of cell exfoliation form another type of stool marker18 
Detection of molecular markers for colorectal neoplasia in feces has the potential to 
improve performance of simple noninvasive screening tests for colorectal cancer. DNA 
methylation markers are a good option for CRC screening even more because DNA 
methylation is an early event in colorectal development, preceding even chromosomal 
abnormalities and mutations. In chapter 7, a new methylation marker, namely Phosphatase 
and Actin Regulator 3 (PHACTR3), was identified from a pool of potential candidates. 
This biomarker for the early detection of colorectal cancer in stool was subsequently 
evaluated for its potential complementary value to a Fecal Immunochemical Test (FIT).
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Colonoscopy-controlled intra-individual 
comparisons to screen relevant neoplasia: 
faecal immunochemical test vs. 
guaiac-based faecal occult blood test
F.A. Oort*, J.S. Terhaar sive Droste*, R.W.M. van der Hulst, H.A. van Heukelem, 
R.J.L.F. Loffeld, I.C.E. Wesdorp, R.L.J. van Wanrooij, L. de Baaij, E.R. Mutsaers, 
S. van der Reijt, V.M.H. Coupe, J. Berkhof, A.A. Bouman, G.A. Meijer, C.J.J. Mulder
*These authors have contributed equally to the work.
Aliment Pharmacol Ther 2010; 31(3): 432-439
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ABSTRACT
Background: Guaiac-based faecal occult blood tests (g-FOBTs) are most commonly 
used in colorectal cancer (CRC) screening programmes. Faecal immunochemical 
tests (FITs) are thought to be superior. 
Aim: To compare performance of a g-FOBT and a quantitative FIT for detection of 
CRCs and advanced adenomas in a colonoscopy-controlled population.
Methods: We assessed sensitivity and specificity of both FIT (OC-sensor) and 
g-FOBT (Hemoccult-II) prior to patients’ scheduled colonoscopies. 
Results: Of the 62 invasive cancers detected in 1821 individuals, g-FOBT was positive 
in 46 and FIT in 54 (74.2% vs. 87.1%, P=0.02). Among 194 patients with advanced 
adenomas, g-FOBT was positive in 35 and FIT in 69 (18.0% vs. 35.6%, P<0.001). 
Sensitivity for screen relevant tumours (197 advanced adenomas and 28 stage I or II 
cancers) was 23.0% for g-FOBT and 40.5% for FIT (P<0.001). Specificity of g-FOBT 
compared to FIT for the detection of cancer was 95.7% vs. 91.0%, P<0.001) and for 
advanced adenomas (97.4% vs. 94.2%, P<0.001).
Conclusions: Faecal immunochemical test is more sensitive for CRC and advanced 
adenomas. Sensitivity of FIT for screen relevant tumours, early-stage cancers and 
advanced adenomas, is significantly higher. Specificity of g-FOBT is higher compared 
with FIT.
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INTRODUCTION 
Colorectal cancer (CRC) is a leading cause of cancer death worldwide. Early detection is 
one of the most realistic approaches to reduce CRC-related death. Guaiac-based faecal 
occult blood tests (g-FOBTs) were already proposed for this purpose in the early 1970s.1 
Blood, shed into the colonic lumen by colorectal adenomas and carcinomas yields a 
positive g-FOBT because of the peroxidase-like activity of haeme in stool.2 Screening 
programmes using g-FOBT have proven to reduce both incidence and mortality of 
CRC.3-7 Yet, both clinical sensitivity (i.e. the percentage of tumours detected in a series 
of tumour positive patients that perform the test) and programme sensitivity (i.e. the 
percentage of tumours present in a population intended to screen that actually is detected) 
are suboptimal.8,9
More recently, the faecal immunochemical test (or FIT), has been introduced as an 
alternative to g-FOBT. The FIT selectively detects the human globin-protein in stool, 
making it specific to colonic blood loss, while globin from blood lost proximal to the 
colon will be degraded before entering the colon.10,11 Several variants of FIT exist, some 
of which come with automated analysis and have quantitative outcomes, like the one 
used in the present study.12
Comparisons of different techniques to detect occult blood in stool have been performed 
since 1953.13 Recent studies that compared g-FOBT and FIT in screening populations 
indicated superiority of FIT for the detection of both cancers and advanced adenomas.8,14,15 
To evaluate whether FIT can replace the most commonly used test (g-FOBT) in CRC 
screening, a comparative study design is needed. Both g-FOBT and FIT should be 
performed in parallel on the same stool samples.14-16
In addition, to appraise specificity of a test directly, all test negative individuals should 
undergo the test that is considered the gold standard, colonoscopy. Inherent to the design 
of screening studies, only FOBT-positive individuals underwent colonoscopy.8,14,15,17 A 
large scale comparison of g-FOBT and FIT in a colonoscopy controlled population is 
still lacking. In the present study, test characteristics of both tests could be determined 
directly, as colonoscopy was performed in all included participants.
While population-based screening studies yield crucial information on programme 
sensitivity and acceptance of a test in the target population, often only small numbers 
of CRCs are detected.18 Consequently, the power to stratify these cancers by stage is 
insufficient.8,19 In a referral population, like in the present study, a higher prevalence of 
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CRC and its precursor lesions will allow for stratification of FOBT result for different 
phases of the natural history of the disease.
AIM
The aim of the present study was an intraindividual comparison of test performance of a 
g-FOBT and a quantitative FIT for detection of CRCs of all stages and advanced adenomas 
in a colonoscopy controlled population. In addition, a specific aim was to compare test 
performance of both tests for the detection of early-stage cancers and advanced adenomas 
taken together, as these lesions are most relevant for screening.
METHODS 
Study population
Five hospitals in the Amsterdam area in the Netherlands participated in this study. From 
June 2006 to March 2008, all ambulatory patients ≥18 years, scheduled for colonoscopy 
were invited to participate in this study regardless of the indication for colonoscopy. 
Two of these five participating hospitals are situated in rural areas, another two are large 
teaching hospitals with an urban population. One of the centres is an academic medical 
centre with a predominantly urban population. In all centres, local Medical Ethics Review 
Board approval was obtained prior to the start of the study, and informed consent was 
obtained from the participants.
Inclusion and exclusion criteria
All eligible individuals were asked to perform both types of FOBT in the week preceding 
colonoscopy. Neither patients who presented at an emergency room nor institutionalized 
patients were enrolled. All indications for colonoscopy, as stated by the referring 
physicians, were recorded. Patients with a documented history of inflammatory bowel 
disease (IBD) or with an incomplete colonoscopy were excluded from further analysis 
as were patients who failed to complete both tests.
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Study design
Elective patients were invited to participate either by their gastroenterologist when 
visiting the outpatient clinic or by telephone by one of five researchers based at each of the 
participating centres. Once a patient consented in participation, an envelop was sent to 
his ⁄ her home address containing background information on the study, both FOBTs with 
extensive instructions and an informed consent form. When a person could not be reached 
over the telephone, the same package was sent but with an additional explanatory letter.
FOBTs
The tests compared were the widely used guaiac-based FOBT; Hemoccult-II (Beckman 
Coulter Inc., Fullerton, CA, USA) and an automated quantitative FIT: OC-sensor (Eiken 
Chemical Co., Tokyo, Japan).
Faecal sampling
The three test-cards of the g-FOBT were sampled with stool from three separate bowel 
movements over a period of 1 week and 7, 3 and 1 day(s) prior to colonoscopy respectively 
(Figure 2.1). On the g-FOBT test cards, two separate samples from different parts of the 
stool had to be applied using the enclosed cardboard sticks. The final test card for g-FOBT 
and the FIT were sampled with stool taken from the day before colonoscopy, and before 
bowel preparation had started. Illustrated instructions guided the participants to sample 
their stool ensuring that contact with water or urine was prevented. No restrictions were 
made with regard to either diet or use of medication during the week in which stool 
samples were taken.20
Test analysis
On the day of colonoscopy, both the completed FOBTs and the informed consent form 
were handed over to the nursing staff at the endoscopy-department. All FITs were stored 
at minus 5 degrees Celsius on arrival and all g-FOBTs were stored at room temperature 
according to the manufacturer’s recommendations. Tests were analysed according to the 
manufacturer’s instructions within 1 week by two experienced technicians, who were 
unaware of the clinical data.21 Both technicians were tested negative for colour blindness 
and received special training for reading the test cards. 
22
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Faecal immunochemical test samples were processed with the OC-sensor MICRO desktop 
analyser (Eiken Chemical Co., Tokyo, Japan).21 A haemoglobin concentration of ≥100 ng 
⁄mL was taken as cut off, according to the manufacturer’s recommendations. G-FOBT 
samples were considered positive when a blue colour appeared in at least one out of three test 
cards, following application of the reagent. Test cards were not rehydrated prior to analysis.
Colonoscopy
All participants underwent complete colonoscopy in one of five participating centres. 
Colonoscopies were performed, or supervised, by experienced gastroenterologists. 
Conscious sedation using Midazolam was offered to all patients. Endoscopists were 
blinded to the results of both tests. A complete colonoscopy was defined as intubation of 
the caecum with identification of the ileocecal valve or appendiceal orifice, or intubation 
up to an obstructing neoplasm. In addition, patients with inadequate bowel cleansing, 
as judged by the individual endoscopist, were excluded as well. Patients were classified 
 
3rd Hemoccult® 
test card
1st Hemoccult® 
test card
Invitation through telephone
Tests sent by mail
2nd Hemoccult® 
test card
OC-sensor®  
100ng/ml
Colonoscopy
 t=0 (n=2217)
1st stoolsample
(t= -7 days)
2nd stoolsample
(t= -3 days)
 3rd stoolsample
(t= -1 day)
Patients scheduled for elective colonoscopy
Participating Centres (n=5)
Exclusion
(n=396)
Inclusion 
(n=1821)
Bowel Lavage
Figure 2.1 Study design.
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based on the most advanced lesion detected in their colon. Estimated size of all lesions, 
as reported in the colonoscopy report, were categorized.
Detected lesions
Histology of tissue samples obtained during colonoscopy was evaluated according to 
standard procedures. Pathology reports were collected centrally and entered into the 
database. Adenomas ≥1.0 cm, with any villous features (i.e. tubulovillous or villous 
adenoma) or highgrade dysplasia, were considered advanced adenomas.22,23 Advanced 
neoplasia included all cases of CRC and all advanced adenomas. Colorectal carcinomas 
were staged according to the AJCC cancer staging manual.24
Statistical analysis
Defining colonoscopy outcome as gold standard, sensitivity and specificity of both 
FOBTs were calculated, for advanced adenomas and for CRC separately. Furthermore, 
these test characteristics were calculated for all participants with either one or more 
advanced adenoma(s) or an early-stage carcinoma (AJCC stages I and II). Since both 
FOBTs were performed in parallel on the same stool samples, McNemar’s test could be 
used for comparison of correlated proportions.
The sample size was predetermined, based on an anticipated difference in sensitivity for 
detection of CRC of 20% between Hemoccult-II and OC-sensor. The enrolment of 1650 
participants was required, assuming a prevalence of CRC of at least 2.5% in this study 
population, to provide the study with a statistical power of 80% to detect a significant 
difference at a two-sided alpha level of 0.05 with the use of McNemar’s test. All analyses 
were performed using SPSS for Windows Version 15 (SPSS Inc., Chicago, IL, USA).
RESULTS
Demographics
Overall, 2,217 individuals who underwent colonoscopy performed at least one of both 
FOBTs. In total, 396 individuals were excluded for reasons listed in Table 2.1. The mean 
age of 1,821 individuals that were included for final analysis was 59.6 years (range 18–86 
years, 95% CI 59.0–60.1). A majority of the subjects (56.9%) were women.
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Indications for colonoscopy
The primary indication for colonoscopy was available for 1,742 out of 1,821 individuals. 
In 79 patients (4.3%), the primary indication remained unspecified. Indications were 
classified in four categories listed in Table 2.2. Almost half of the population (N=897, 
49.3%) was referred for colonoscopy because of gastrointestinal symptoms and 44.3% 
of patients was asymptomatic and had an indication for screening or surveillance 
colonoscopy (N=807).
Colonoscopy results
In 194 of 1,821 patients (10.7%), at least one advanced adenoma was found on colonoscopy. 
Adenocarcinomas were found in 62 of 1,821 patients (3.4%). Of these, 28 (45.2%) were 
classified as early-stage CRC (AJCC stages I and II) and 31 patients (50.0%) as late stage 
(AJCC stages III and IV). Three rectal cancers could not be accurately staged due to the 
effects of neo-adjuvant radiotherapy.
Test results
Overall positivity rate for the g-FOBT was 6.7% (122⁄1821) and for the FIT 11.8% 
(214⁄1,821). The g-FOBT detected 46 of 62 cancers for a sensitivity of 74.2%, whereas the 
FIT detected 54 of 62 cancers, for a sensitivity of 87.1% (Table 2.3). FIT detected seven 
Table 2.1 Reasons for exclusion of 396 patients out of 2,221 consecutive patients undergoing 
colonoscopy in five hospitals in the Amsterdam area
Reason for exclusion N=396 (100%)
Incomplete colonoscopy
Caecum not reached 102 (25.8)
Insufficient bowel lavage 27 (6.8)
Documented history of IBD 77 (19.4)
FIT not sampled 87 (22.0)
g-FOBT not sampled 98 (24.7)
Colostomy 5 (1.3)
IBD, inflammatory bowel disease; FIT, faecal immunochemical test; g-FOBT, guaiac-based faecal occult 
blood tests.
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cancers that did not score a positive g-FOBT. Only one cancer scored a positive g-FOBT 
but not a positive FIT. The observed difference in sensitivities between the two tests was 
significant (P=0.02). Sensitivity for screen relevant lesions (advanced adenomas and 
earlystage cancers) was 23.0% for g-FOBT and 40.5% for FIT (P<0.001).25 Yet, g-FOBT 
was found to have a higher specificity compared to FIT for cancers of all stages (95.7% 
vs. 91.0%, P<0.001) and for advanced adenomas (97.4% vs. 94.2%, P<0.001).
The difference between sensitivities of g-FOBT and FIT for the detection of early or late-
stage CRCs respectively showed a similar trend but did not reach statistical significance. 
The sensitivities of g-FOBT and FIT for early-stage cancers was 57.1% and FIT 75.0% 
respectively (Table 2.4). For late-stage cancers, g-FOBT had a sensitivity of 87.1% and 
FIT 96.8%.
Table 2.2 Primary indications for colonoscopy among 1,821 consecutive patients in five 
hospitals in the Amsterdam area enrolled in a study comparing faecal immunochemical test 
vs. guaiac-based faecal occult blood tests
Indication group Indication for colonoscopy N
Symptomatic/suspect Weight loss 15
Clinical suspicion of diverticulitis 14
Clinical suspicion of IBD 17
Abdominal pain 280
Anaemia 77
Haematochezia 190
Altered bowel habits 304
Clinical suspicion of CRC (inconclusive pathology) 1
Colonoscopy for polypectomy 37
Total 935
Screening and surveillance Average risk 32
Familial history of CRC 288
Lynch syndrome 29
Polyp surveillance 314
Post CRC surveillance 120
Radiological suspicion of malignancy 21
Total 804
Other Not specified 82
Grand total 1,821
IBD, infl ammatory bowel disease; CRC, colorectal cancer.
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DISCUSSION
In this study, performance characteristics of both g-FOBT and FIT were evaluated in 
parallel in a referral population of 1,821 patients who underwent complete colonoscopy. 
This design allowed to deal with two major issues that, thus far, have remained 
unaddressed. First, in most studies so far on FIT, only individuals with a positive test 
underwent subsequent colonoscopy, which precluded the determination of false negativity 
rates and thus specificity of the investigated tests. Secondly, previous studies comparing 
g-FOBT and FIT did so mainly in separate patient groups, which limit determination of 
exactly which tumours are missed by one test but are detected by the other.
Overall, results of the present study are consistent with earlier observations in screening 
studies and confirm a significantly higher sensitivity of FIT for CRC as well as advanced 
adenomas. The referral population that was evaluated in the present study consisted 
of more individuals with CRC or advanced adenomas than an average risk screening 
population. For reasons of the relatively high tumour yield in the referral population 
in the present study, test results of FIT and g-FOBT could be stratified for early-stage 
cancers (AJCC stages I and II) and late-stage cancers (stages III and IV). Importantly, 
for the screen relevant neoplasia (i.e. advanced adenomas and early-stage cancers taken 
together), FIT significantly outperforms g-FOBT in terms of sensitivity with 40.5% 
vs. 23.0% respectively. This is of special importance as population-based screening 
programmes for CRC aim to detect this category of neoplasia specifically. A trend in the 
same direction was observed in early-stage cancers alone, with detection rates of 75.0% 
vs. 57.1% for FIT and g-FOBT respectively, but this did not reach statistical significance.
Table 2.4 Test outcome of guaiac-based faecal occult blood tests (Hemoccult-II) and faecal 
immunochemical test (OC-sensor) in 62 patients diagnosed with colorectal cancer at an early 
stage (N=28) and at a late stage (N=31)
Hemoccult-II OC-sensor
TotalPositive Negative Positive Negative
Early stage disease (stages I and II) 16 (57.1) 12 (42.9) 21 (75.0) 7 (25.0) 28
Late stage disease (stages III and IV) 27 (87.1) 4 (12.9) 30 (96.8) 1 (3.0) 31
AJCC stage unknowna 3 0 3 0 3
Total 46 (74.2) 16 (25.8) 54 (87.1) 8 (12.9) 62 (100)
Values within parenthesis represent percentages.
a Three rectal tumours could not be accurately staged because of the effects of neo-adjuvant radiotherapy.
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In a screening-naive population, both early and late-stage CRCs, the so called prevalent 
cancers, will be detected in a range consistent with their respective prevalence. Therefore, 
in a first round of a screening programme, overall CRC detection rates will be inflated by 
the prevalent advanced stage cancers. However, given the nature of the disease, with usual 
annual or bi-annual screening programmes, in a second round of screening, less advanced 
cancers will be left in the population.26 Therefore, the performance characteristics of the 
screening programme will largely depend on the potential to detect early-stage CRCs, 
i.e. incident cancers. In this respect, it is highly relevant that the present study allowed 
to analyse performance of both tests separately for early and late-stage CRC. Preferably, 
these results need to be validated in a screening population, but the small numbers of 
CRCs detected in screening studies will hamper such a study design.
Positive and negative predictive values of a test are influenced by the prevalence of a 
disorder in the population that is tested. Therefore, in this referral population, these values 
were not calculated as they would not reflect predictive values in a screening population. 
However, sensitivity and specificity are characteristics of a diagnostic test and are not 
influenced by the prevalence of a disease in population.27
With respect to whether the present findings are generalizable to a screening population, 
it could be argued that preclinical (i.e. screen detected lesions) may be different (e.g. in 
their tendency to bleed) from symptomatic lesions. However, so far, there is no evidence 
that either supports or falsifies this hypothesis. 
The present study shows that the higher sensitivity of FIT goes at the cost of a somewhat 
lower specificity (advanced neoplasia; 97.4% vs. 94.2%, overall cancer; 95.7% vs. 91.0%, 
for g-FOBT and FIT, respectively). The higher specificity of g-FOBT compared to FIT, 
was recently described in another study comparing exactly the same g-FOBT and FIT, 
but in two separate populations.8 In this study that used a population screening design, 
specificity could not be calculated directly, as only FIT or g-FOBT positive individuals 
were offered colonoscopy. Hence, specificities were calculated based on rare disease 
assumptions. This may explain the small differences in specificity between their study 
and the current one in which all individuals underwent colonoscopy. Moreover, not all 
guaiac-based FOBTs have the same test characteristics. The Hemoccult-II used in the 
present study is a low sensitivity FOBT. The US only endorse the use of sensitive g-FOBTs 
(e.g. Hemoccult Sensa) for screening and therefore the results might be different if an 
FOBT with better sensitivity was used.28
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Apart from the higher sensitivity for screen relevant tumours, FIT has several other 
advantages. The technical characteristics of the FIT test used in the present study allow 
for automated analysis, unlike g-FOBT, which makes it suitable for high throughput 
application. Furthermore, patient acceptance of a test is a major determinant of compliance 
and consequently success of a screening programme. The OC-sensor has been found to 
be significantly better accepted by the average risk target population for CRC screening 
than the Hemoccult-II.8 Finally, the reproducibility and quality control of FIT are good, 
where g-FOBT was not optimal.29,30
Secondary prevention of CRC is a major health care issue, and several countries 
already have introduced g-FOBT in large pilot-studies or nationwide CRC screening 
programmes.31,32 A growing body of literature lends support to the notion that FIT 
is superior to g-FOBT in CRC screening.8,15,17,33,34 The present study adds to this the 
observation that FIT has a significantly higher sensitivity for screen relevant tumours 
than g-FOBT. In addition, the present study allows for a more precise estimation of the 
specificity of FIT for colorectal tumours.
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ABSTRACT
Background: Adjusting the threshold for positivity of quantitative fecal immuno-
chemical tests (FIT) allows for controlling the number of follow-up colonoscopies 
in a screening program. However, it is unknown to what extent higher cut-off levels 
affect detection rates of screen-relevant neoplasia. This study aimed to assess the 
effect of higher cut-off levels of a quantitative FIT on test positivity rate and detection 
rate of early-stage colorectal cancers (CRC). 
Methods: Subjects above 40 years old scheduled for colonoscopy in 5 hospitals 
were asked to sample a single FIT (OC sensor) before colonoscopy. Screen-relevant 
neoplasia were defined as advanced adenoma or early-stage cancer (stage I and II). 
Positivity rate, sensitivity, and specificity were evaluated at increasing cut-off levels 
of 50 to 200 ng/mL. 
Results: In 2,145 individuals who underwent total colonoscopy, 79 patients were 
diagnosed with CRC, 38 of which were with early-stage disease. Advanced adenomas 
were found in 236 patients. When varying cut-off levels from ≥50 to  ≥200 ng/mL, 
positivity rates ranged from 16.5% to 10.2%. With increasing cut-off levels, sensitivity 
for early-stage CRCs and for screen-relevant neoplasia ranged from 84.2% to 78.9% 
and 47.1% to 37.2%, respectively.
Conclusions: Higher FIT cut-off levels substantially decrease test positivity rates 
with only limited effects on detection rates of early-stage CRCs. However, spectrum 
bias resulting in higher estimates of sensitivity than would be expected in a screening 
population may be present.
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INTRODUCTION 
Screening for colorectal cancer (CRC) using guaiacbased fecal occult blood tests (G-FOBT) 
has been shown to reduce CRC-related mortality.1-3 In recent years, a growing body of 
literature lends support to the notion that fecal immunochemical tests (FIT) are superior 
to G-FOBT in CRC screening.4-8 This superiority does not only imply higher participation 
rates and sensitivity for advanced neoplasia, but also better reproducibility and quality 
control due to the automated analysis and quantitative test output.9 The quantitative 
test output allows for adjusting the threshold for the definition of a positive test. This is 
important because several recent studies comparing G-FOBT and FIT have reported a lower 
specificity of FIT when a cut-off level of 50 to 100 ng hemoglobin/mL was used.5-8 Once 
this test is applied in a CRC screening program, a lower cut-off level will result in more 
screenees being referred for colonoscopy, and due to lower specificity, a higher number 
of futile colonoscopies. Higher FIT cut-off levels will decrease strain on colonoscopy 
resources, but might also be associated with more curable CRCs being undetected. To test 
this hypothesis, a study design is needed in which all FIT-negative individuals undergo 
the reference test, that is, complete colonoscopy. However, in most populationbased 
screening studies, only FIT-positive individuals undergo colonoscopy.4-7,10,11 Although 
these screening studies reflect the target population for screening, sensitivity cannot be 
calculated. Specificity can be calculated, but only indirectly and based on less accurate 
rare disease assumptions.6 Moreover, these studies often have a low yield of CRCs, which 
restricts the power to stratify these cancers by stage.6,7,12,13 When aiming at CRC mortality 
reduction, detection of early-stage cancers is much more relevant than detecting late-stage 
cancers. In a referral population, like in the present study, a higher prevalence of CRC and 
its precursors will allow for stratification of quantitative FIT results for different phases 
of the natural history of the disease. We therefore assessed the effect of a higher cut-off 
level of a quantitative FIT on positivity rates and on detection rates of curable, early-stage 
CRCs and advanced adenomas in a colonoscopycontrolled population.
PATIENTS AND METHODS 
Study population and study design
Details of study design and of most materials and methods relevant for this study have 
been published previously in a report on the direct comparison of a FIT and a G-FOBT.8
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All ambulatory subjects over the age of 40 years scheduled to undergo elective colonoscopy 
from June 2006 to January 2009 at 1 of the 5 participating hospitals were invited to 
participate in this study. Invitation was either in person by the referring gastroenterologist 
or through telephone by 1 of 5 research workers stationed at each of the participating 
centers. Once subjects consented in participation, they received an envelope containing 
background information on the study, the FIT with extensive instructions, and an 
informed consent form. When an individual could not be reached by telephone, the same 
package was sent but with an additional explanatory letter. Two of these 5 participating 
hospitals are situated in rural areas, another two are large teaching hospitals with an urban 
population. One of the centers is an academic medical center with a predominantly urban 
population. In all centers, local Medical Ethics Review Board approval was obtained prior 
to the start of the study.
All eligible individuals were asked to sample one FIT on stool from a bowel movement 
on the day prior to colonoscopy. Patients with a documented history of inflammatory 
bowel disease (IBD), subjects who failed to complete the test and subjects in whom no 
written informed consent was obtained were excluded from further analysis. We also 
excluded subjects with incomplete colonoscopies and subjects with inadequate bowel 
cleansing, as judged by the endoscopist.
Fecal immunochemical tests
The FIT used in the present study is the automated quantitative OC-sensor test (Eiken 
Chemical Co.). The FIT was sampled from stool produced the day before colonoscopy 
and bowel preparation had started. Subjects were excludedwhen the FITwas sampled after 
initiation of bowel preparation. Illustrated instructions guided the participants to sample 
their stool ensuring that contact with water and urine was prevented. Norestrictions 
weremade with regard to diet during the week in which the stool sample was taken.14 
Participants were asked to discontinue anticoagulants and NSAIDs (nonsteroidal 
antiinflammatory drugs) 5 days prior to colonoscopy. On the day of colonoscopy, the 
completed test and the signed informed consent form were handed over to the nursing 
staff at the endoscopy department. All FITs were stored at -5° C on arrival. Tests were 
analyzed using the OC sensor MICRO desktop analyzer (Eiken Chemical Co.) according 
to the manufacturer’s instructions.15 Tests were analyzed within 1 week by 1 of the 2 
experienced technicians who were unaware of the clinical data. Both technicians received 
special training for analyzing the tests.
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Standards of reference
Colonoscopy was the standard of reference for the presence, size, and location of colorectal 
neoplasia. Colonoscopies were performed or supervised by experienced gastroenterolo-
gists. Endoscopists were blinded to the FIT result. Conscious sedation using midazolam 
was offered to all patients. A complete colonoscopy was defined as intubation of the 
cecum with identification of the ileocecal valve or appendiceal orifice, or intubation up 
to an obstructing neoplasm. The results of histopathologic analysis of tissue samples ob-
tained during colonoscopy were the standard of reference for the diagnosis of adenoma 
or cancer. Surgical resection specimens were used for the standard of reference for CRC 
staging. If no surgical resection had been performed, the results of histopathologic bio-
psy specimens were used instead. Adenomas of size 1.0 cm or greater, with any villous 
features (i.e., tubulovillous or villous adenoma) or high-grade dysplasia, were considered 
advanced adenomas.16,17 Advanced neoplasia included all cases of CRC and all advanced 
adenomas. Colorectal carcinomas were staged according to the AJCC (American Joint 
Committee on Cancer) cancer staging manual.18 Early-stage CRC was defined as AJCC 
stage I or II, whereas late-stage CRC was defined as AJCC stage III or IV. Because the 
ultimate goal of screening is the detection of early stages of diseases, we defined screen-
relevant neoplasia as one or more advanced adenoma(s) or early-stage CRC.8,19 If multiple 
lesions were present, classification was based on the most advanced lesion found.
Statistical analysis
Taking colonoscopy as the reference test, sensitivities and specificities of FIT at 6 cut-
off levels were calculated for the following colonoscopy outcomes: (i) the presence of 
CRC; (ii) the presence of early-stage CRC; (iii) the presence of advanced adenoma; (iv) 
the presence of screen-relevant neoplasia; and (v) the presence of advanced neoplasia. 
The sensitivity is calculated as the proportion of positive test results in patients with the 
colonoscopy outcome under consideration. The specificity is calculated as the proportion 
of negative test results in patients with an outcome less severe than the colonoscopy 
outcome under consideration. Note that, therefore, the same specificity results from 
choosing either outcome 1 (all stages of CRC) or outcome 2 (early-stage CRC), and from 
choosing either outcome 3, 4, or 5. For dichotomizing the FIT results, we used cut-off 
levels of 50, 75, 100, 125, 150, and 200 ng hemoglobin/mL, which are levels frequently 
used in FIT studies (7, 20, 21). The calculations were repeated for the subgroup of patients 
that are considered at low risk for colonic neoplasia (procedure indications: abdominal 
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pain, constipation, and screening colonoscopy in average risk individuals) as well as for 
the high-risk subgroup separately.
We used receiver operator characteristic (ROC) curve analysis, including calculation 
of the area under the curve (AUC) with 95% CIs to evaluate the relation between the 
quantitative FIT outcome and (i) the presence of CRC; (ii) the presence of early-stage 
CRC; (iii) the presence of advanced adenoma; and (iv) the presence of screen-relevant 
neoplasia. All analyses were performed with SPSS for Windows Version 15 (SPSS Inc.).
Patients scheduled for elective colonoscopy in 5 participating
hospitals who performed the FIT (n = 2,525)
Exclusion:
Documented history of IBD (n = 22) 
FIT inadequately sampled (n = 3)
Age < 40 years (n = 165)
Exclusion:
Incomplete colonoscopy (n = 168) 
Insufficient bowel lavage (n = 13)
Colostomy (n = 7)
Exclusion:
No histopathological diagnosis (n = 2)
Patients undergoing colonoscopy (n = 2,335)
Patients with a total colonoscopy and sufficient bowel cleansing
(n = 2,147)
Patients included for final analysis (n = 2,145)
Figure 3.1 Study flow diagram. FIT, faecal immunochemical test; IBD, inflammatory bowel 
disease.
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RESULTS
Characteristics of the study population
Overall 2,525 individuals who underwent colonoscopy sampled a FIT. In total, 380 
individuals were excluded (Figure 3.1). The mean age of the 2,145 individuals that were 
included for final analysis was 61.8 years (range = 40–89 years) and 53.8% of these were 
female. Colonoscopy was performed because of gastrointestinal symptoms in 1,109 
individuals (51.7%), whereas screening or surveillance for CRC was the indication for 
colonoscopy in 955 asymptomatic individuals (44.5%). Of 81 individuals (3.8%), the 
primary indication remained unspecified (Table 3.1).
Table 3.1 Primary indications for colonoscopy among 2,145 consecutive patients in 5 hospitals 
in the Amsterdam area enrolled in a study comparing sensitivities for early-stage cancers at 
different FIT cut-off levels
Indication group Indication for colonoscopy N
Symptomatic/suspect
Weight loss 20
Clinical suspicion of diverticulitis 22
Clinical suspicion of IBD 17
Abdominal pain 297
Anaemia 97
Hematochezia 237
Altered bowel habits 253
Constipation 35
Diarrhea 81
Clinical suspicion of CRC (inconclusive histology) 1
Colonoscopy for polypectomy 49
Total 1,109
Screening and surveillance
Average risk 42
Familial history of CRC 319
Lynch syndrome 24
Polyp surveillance 396
Post CRC surveillance 147
Radiological suspicion of malignancy 25
Screening for CRC in celiac disease 2
Total 955
Other
Not specified 81
Grand total 2,145
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Colonoscopy results
CRCs were found in 79 individuals (3.7%). Of these CRCs, 38 (48.1%) were classified as 
early stage (AJCC stage I or II) and 36 (45.6%) were classified late stage (AJCC stage III 
or IV). For 5 rectal cancers (6.3%), stage could not be determined accurately due to the 
effects of neoadjuvant radiotherapy. In 236 individuals (11.0%), at least one advanced 
adenoma was found. This resulted in 315 individuals with advanced neoplasia (either 
advanced adenoma or CRC) and 274 individuals with screen-relevant neoplasia (either 
advanced adenoma or early-stage CRC).
FIT results
The overall FIT positivity rates at the different cut-off levels varied from 16.5% (N=354 
at cut-off  ≥50 ng/ml) to 10.2% (N=218 at cut off  ≥200 ng/ml). Table 3.2 shows the test 
characteristics of FIT at different cut-off levels to detect CRC, early-stage CRC, late-
stage CRC, advanced neoplasia, screen-relevant neoplasia, and advanced adenomas. 
Table 3.3 summarizes the sensitivities and positivity rates for early-stage CRC and for 
screen-relevant neoplasia.
ROC curves for FIT
The AUC of the ROC curve for the detection of CRC (N=79) was 0.93 (95% CI: 0.89–
0.96). For the detection of early-stage CRC (N=38), an AUC of 0.89 was found (95% CI: 
0.82–0.95). When all screen-relevant neoplasia were considered (N=274), the AUC was 
0.72 (95% CI: 0.68–0.76). The AUC for the detection of advanced adenomas separately 
(N=236) was 0.69 (95% CI: 0.65–0.73).
Sensitivities in high- versus low-risk populations
Sensitivities of FIT for CRC, early-stage CRC, and screen-relevant neoplasia were com-
pared between indication groups that were considered at low risk for colonic neoplasia 
versus at high risk. Patients with procedure indications like abdominal pain, constipation, 
and screening colonoscopy in average risk individuals were considered to belong to a 
low-risk population (N=374). The remaining procedure indications were considered to 
reflect a high risk population (N=1,771; Table 3.1). Sensitivity and the yield of screen-
relevant lesions in these 2 populations are shown in Table 3.4.
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DISCUSSION
In the present study, test performance of one of the most commonly used FITs was evaluated 
at different cut-off levels in a large cohort of individuals undergoing colonoscopy. It was 
found that by increasing the cut-off level specificity increased substantially, whereas the 
effects on detection rates of curable, early-stage CRCs were only limited.
Although many other aspects have to be taken into account when deciding on the most 
suiting cut-off level, this study has its focus on sensitivity and specificity. In general, the 
FIT showed to have good test characteristics for detecting both CRC and early-stage 
CRC, as reflected by the AUC in the ROC curves. Adjusting the cut-off level from 
 ≥50 to  ≥200 ng/mL resulted in a substantial decrease in the number of positive tests 
(16.5%–10.2%). Compared with a cut-off level of  ≥50 ng/mL, 2 early-stage cancers would 
have been missed at a cut-off level of greater than 200 ng/mL. In fact, from a cut-off 
level of ≥ 125 ng/mL upward, no further decrease in sensitivity was found. Specificity, 
however, increased from 86.4% to 92.8% with increasing cut-off levels. Focusing on all 
screen-relevant neoplasia, 47.1% were detected with the lowest cut-off level of 50 ng/mL 
or greater, whereas the highest cut-off level of 200 ng/mL or greater yielded only 37.2% 
of all screen-relevant lesions. 
Consequences of these findings depend on the setting in which FIT is applied. The choice 
for a higher FIT threshold may be particularly relevant when a screening program is to 
be implemented, like is planned for the Netherlands.22 The Dutch Health Council advised 
to start screening at a cut-off level of 75 ng/mL, even though using 50 ng/mL might be 
more cost-effective.22 However, current colonoscopy capacity is insufficient to cope with 
positive screenees at this cut-off level. A higher FIT cut-off level will limit the number 
of colonoscopy referrals. In the first round of a screening program, both early- and late-
stage CRCs, so called prevalent cancers, will be detected in a range consistent with their 
respective prevalences in a screening-naive population. So, in the first round, yield and 
thus strain on the health care system, will be inflated by the prevalent advanced-stage 
CRCs. In later rounds of screening, however, less advanced CRCs will be left in the 
population and the performance characteristics of the screening program will largely 
depend on the potential to detect early-stage CRCs, that is, incident cancers. In this respect, 
it is highly relevant to know that increasing the cut-off level to 200 ng/mL or greater has 
a relatively small effect on the sensitivity to detect early-stage cancers when starting a 
CRC screening program. The lower positivity rate and the higher specificity will result 
in less referrals for colonoscopy with an acceptable decrease in detection rates. When 
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the prevalence of target lesions would decrease in later screening rounds, cut-off levels 
can easily be adjusted to lower values to achieve a more sensitive program. The miss rate 
for advanced adenomas at a higher cut-off level is somewhat higher (70% at >200 ng/mL 
vs. 59% at 50 ng/mL). Given the natural history of the disease, an advanced adenoma 
that would be missed in the initial screening round would have multiple opportunities 
to be detected in a consecutive round, either still at the stage of an advanced adenoma 
or as an early-stage cancer.
The colonoscopy-controlled referral population used in the present study has 2 advantages 
compared with a screening population. Firstly, in most FIT studies to date, only 
individuals with a positive test underwent subsequent colonoscopy. This precluded the 
determination of sensitivity, false-negative rates and thus specificity of the investigated 
tests. The present study design provides accurate data on direct sensitivity of the FIT at 
different cut-off levels. Secondly, the referral population contained a higher number of 
individuals with CRC or advanced adenomas compared with an average risk screening 
population. Consequently, FIT results could be stratified by stage of the disease. More 
precise data on sensitivity and specificity, that is with smaller CIs than data from screening 
studies in which there is a lower prevalence of target lesions, could be calculated.4,6,7,20,23 
In screening studies, specificities are calculated on the basis of rare disease assumptions. 
This may lead to overestimation of specificity.24 Although sensitivity and specificity are 
characteristics of a diagnostic test and are not dependent on the prevalence of disease, 
specificity can still be underestimated in the present study because the subjects are at 
higher risk of other potentially bleeding disorders than the general population.25 When 
comparing data on specificity for advanced neoplasia of the present study with those 
reported in screening study designs using the same FIT, the present series shows lower 
specificities (89.9%–95.8% in the present study compared with 95.5%–98.8% in other 
studies with cut-off levels increasing from  ≥50 ng/ml to  ≥200 ng/ml 7,20). Interestingly, in 
another colonoscopy-controlled study performed in a referral population with a smaller 
sample size, specificities were comparable with the present findings.21 These different 
specificities probably reflect the range of true specificity of the OC Sensor. 
The higher positivity rate of the FIT and higher prevalence of advanced neoplasia in the 
present referral population make it impossible to extrapolate the positive and negative 
predictive values (PPV and NPV) of this study to a screening population. However, by 
applying Bayes’ theorem, the sensitivity and specificity from this study can be combined 
with observed prevalences of CRC and advanced adenomas found in the general population 
47
FIT perform
ance in early stage colorectal cancer
Chapter 3
to estimate the NPV and PPV in the general population.26 Although these computed values 
for NPV and PPV should be interpreted with caution, it allows us to explore the effect of 
increasing cut-off levels. The prevalence of CRC found in Dutch screening studies is 0.8% 
and advanced adenomas are found in 6.7%.22 In the time period from 2003 to 2007, 54% 
of all newly diagnosed CRC patients presented with early-stage disease.27 Increasing the 
cut-off level of FIT from  ≥50 ng/mL to  ≥200 ng/mL hardly affected NPV for early-stage 
CRC (99.9%). The PPV for detection of early-stage cancer, however, increases substantially 
from 2.6% to 4.5%. The number needed to scope reduced significantly by increasing the 
cut-off level to 200 ng/mL or greater, resulting in a 42% decrease in required colonoscopies 
and only a 6% reduction in detection rates of early-stage CRCs.
An important issue is whether the present findings can be generalized to a screening 
population. The use of a referral population to evaluate a screening test carries the risk 
of introducing spectrum bias. Spectrum bias refers to the situation that the spectrum of 
the disease phenotype differs from that in the population in which the test ultimately will 
be applied.28 This might lead to overestimation of sensitivity. An ultimate answer to this 
question can only come from a colonoscopy-controlled screening population. To accrue 
a similar number of cancers in such a study design as in the present study would require a 
very large sample size which might frustrate such a study design. According to the number 
of CRCs found in the 2 large screening trials in the Netherlands, such a study should invite 
30,275 average risk individuals for FIT screening to obtain the same CRC yield as in the 
present study.6,7 This sample size is based on the assumption of a 60% to 62% participation 
rate for FIT and 84% to 95% compliance to colonoscopy after a positive FIT.6,7
Three other lines of evidence provide indications that the effect of spectrum bias in the 
present study may be limited. Firstly, when comparing sensitivities of FIT for screen-
relevant neoplasia in patients from the present study population who could be considered 
to have a low risk for colonic neoplasia to those that would be at higher risk, only minor 
differences in sensitivity were found.29,30 Secondly, spectrum bias could also be explained 
by a different tumor stage distribution in the referral population compared with those in a 
screening population. A comparison of CRCs from a referral and a screening population 
indeed revealed a higher prevalence of advanced cancers. After stratifying for T stage, 
however, no differences in FIT results were found between the screening and referral 
population.31 Thirdly, test characteristics found in screening studies remain debatable, 
as 70% of screen detected CRCs in the British NHS National Bowel Cancer Screening 
Program appeared to be symptomatic.32
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In conclusion, in the present study higher cut-off levels turned out to result in only a 5.3% 
decrease in detection rate for early-stage CRC, whereas at the sametime substantially 
reducing the number of positive FITs with 6.3%. Overestimation of sensitivity, however, 
due to potential spectrum bias can not be ruled out completely. When a higher cut-off 
level would be used as a first step preceding colonoscopy in a CRC screening program, 
lower numbers of colonoscopies would be required. This may facilitate the appropriate 
allocation of available resources. The lower detection rates of advancedadenomasmay be 
overcomeby the fact that these lesions are likely to be detected in a later screening round 
while probably still being at a stage of disease at which death from CRC can be prevented.
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ABSTRACT
Background: A single sampled faecal immunochemical test (FIT) has moderate 
sensitivity for colorectal cancer and advanced adenomas. Repeated FIT sampling 
could improve test sensitivity. The aim of the present study is to determine whether 
any of three different strategies of double FIT sampling has a better combination of 
sensitivity and specificity than single FIT sampling. 
Methods: Test performance of single FIT sampling in subjects scheduled for 
colonoscopy was compared to double FIT sampling intra-individually. Test positivity 
of double FIT sampling was evaluated in three different ways: 1) “one of two FITs+” 
when at least one out of two measurements exceeded the cut-off value, 2) “two of 
two FITs+” when both measurements exceeded the cut-off value, 3) “mean of two 
FITs+” when the geometric mean of two FITs exceeded the cut-off value. Receiver 
operator curves were calculated and sensitivity of single and the three strategies of 
double FIT sampling were compared at a fixed level of specificity. 
Results: In 124 of 1,096 subjects, screen relevant neoplasia (SRN) were found (i.e. 
early stage CRC or advanced adenomas). At any cut-off, “two of two FITs+” resulted 
in the lowest and “one of two FITs+” in the highest sensitivity for SRN (range 35–44% 
and 42–54% respectively). ROCs of double FIT sampling were similar to single 
FIT sampling. At specificities of 85/90/95%, sensitivity of any double FIT sampling 
strategy did not differ significantly from single FIT (p-values 0.07–1).
Conclusion: At any cut-off, “one of two FITs+” is the most sensitive double FIT 
sampling strategy. However, at a given specificity level, sensitivity of any double FIT 
sampling strategy for SRN is comparable to single FIT sampling at a different cut-off 
value. None of the double FIT strategies has a superior combination of sensitivity 
and specificity over single FIT.
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BACKGROUND 
In the United States of America and in Europe, colorectal cancer (CRC) ranks second as 
cause of cancer related death.1,2 Screening is the most realistic approach to decrease CRC 
related mortality. Screening with guaiacbased faecal occult blood tests (g-FOBTs) has 
been shown to decrease disease specific mortality.3-5 Faecal immunochemical tests (FITs 
or i-FOBTs) have been shown to be superior to g-FOBTs.6-9 A major benefit of (semi-)
quantitative FITs is that by adjustment of the threshold for positivity, test characteristics 
and number of follow-up colonoscopies can be tuned to local resources.10,11 Since 
sensitivity of FIT for CRC is in the range of 66–87%,8,12,13 and sensitivity for advanced 
adenomas is even lower (27–38% depending on the cut-off value),8,13,14 there is still room 
for improvement. One approach for improving the sensitivity of FIT based screening could 
be to increase the number of samples tested, which is common practice for gFOBTs.3-5
So far, most studies on double FIT sampling either did not perform colonoscopy in FIT 
negative individuals,15,16 did not evaluate different definitions of positivity for double FIT 
sampling,14,17,19 or did not assess the effect of different cut-off values.17,20 In addition, none 
of these studies evaluated the effect of multiple sampling on specificity.
This prospective, multi-centre cohort study aims to investigate whether sensitivity for the 
detection of screen relevant neoplasia (CRC stage I, II or advanced adenomas) of single 
FIT sampling can be increased by double FIT sampling, without substantially affecting 
specificity. Primary goal is to compare sensitivity and specificity of single FIT sampling 
and different strategies of double FIT sampling, at a predefined range of cut-off values, 
in a colonoscopy controlled population. In this study, we report that double and single 
FIT sampling have a comparable combination of sensitivity and specificity, at a different 
cut-off value.
METHODS 
Study population
From June 2008 to October 2009, all ambulatory patients (≥18 years) scheduled for 
elective colonoscopy in three participating medical centres in and around Amsterdam, 
were invited to participate in this study irrespective of their indication for colonoscopy 
(i.e. screening, surveillance, or presence of symptoms). Exclusion criteria were either 
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hospitalization, age below 18 years, colostomy, total colectomy, colitis with ulcer(s), or a 
documented history or subsequent diagnosis of inflammatory bowel disease (IBD). In 
addition, individuals in which colonoscopic examination remained incomplete due to 
insufficient bowel lavage or technical difficulties, who did not adhere to the instructions 
on FIT sampling (e.g. failed to provide the dates of FIT sampling), or could not provide 
informed consent, were excluded from analysis. The local Medical Ethics Review Boards 
of each of the hospitals approved this study.
Study design
All eligible individuals were asked to perform a FIT on two subsequent days prior to 
colonoscopy. Elective patients were invited to participate in this study by telephone. 
Individuals interested in the study received a more detailed information package by 
mail, including two FITs, sampling instructions and an informed consent form. Subjects 
who could repetitively not be reached by telephone were send the same package with an 
additional explanatory letter.
An automated FIT was used (OC-sensor®, Eiken Chemical Co., Tokyo, Japan). This semi-
quantitative test is considered positive when the haemoglobin concentration in the test 
tube exceeds the pre-determined cut-off value. Patients were instructed to perform this 
test on two separate days, before bowel preparation by laxatives was started, and write 
the date of performance on the FIT container.
The baseline FIT was defined as the sample taken from a bowel movement one day prior 
to colonoscopy (t = -1), whereas the additional FIT for double sampling was performed 
on stool produced two days before colonoscopy (t = -2; see Figure 4.1). Illustrated and 
written instructions explained participants to sample their stool without contamination 
with water or urine. All FITs were sampled at home and there were no restrictions in diet 
or medication during the week in which stool was sampled. Participants were instructed 
to obtain FIT samples at a maximum of 72 hours prior to colonoscopy, and to put the FIT 
samples in the zip lock bags that were included in the mail package. Participants were 
requested to store the zip lock bags in the refrigerator until departure for the endoscopy 
department.
Completed FITs and informed consent forms were collected at the endoscopy-department 
at the day of colonoscopy. All FITs were stored at minus 20 degrees Celsius on arrival. 
Tests were analyzed according to the manufacturer’s instructions by an experienced 
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technician, who was unaware of the clinical data, using the OC sensor MICRO desktop 
analyzer (Eiken Chemical co., Tokyo, Japan).21
Colonoscopy and lesions
All colonoscopies were performed or supervised by experienced gastroenterologists, 
who were unaware of the FIT results. Patients were offered to take conscious sedation 
by Midazolam. A complete colonoscopy was defined as intubation of the caecum 
with identification of the ileocaecal valve or appendiceal orifice, or intubation up to 
CRC (irrespective of the location and visualisation of the whole colon). Incomplete 
colonoscopies or colonoscopies with insufficient bowel preparation, as judged by the 
individual endoscopist, were excluded unless CRC was found. However, if a barium 
enema, virtual colonography or second colonoscopy was performed within six months, 
evaluation of the colon was considered complete and the subject was included in analysis. 
Patients were classified based on the most advanced lesion detected. 
Histology of tissue samples obtained was evaluated routinely. Lesion size was estimated 
by the endoscopist. Adenomas ≥1.0 cm, adenomas with a villous component (i.e. 
Figure 4.1 Study design. FIT, faecal immunochemical test.
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tubulovillous or villous adenoma) or adenomas with high-grade dysplasia were defined 
as advanced adenomas.22 Colorectal carcinoma was staged according to the AJCC cancer 
and TNM staging manual.23 Screen relevant neoplasia were defined as advanced adenoma 
and/or early stage cancer (i.e. stage I and II).
Statistical analysis
Primary outcome measures were sensitivity and specificity of the baseline FIT (t=-1; 
henceforth single FIT) and three strategies for double FIT sampling (results of t=-1 and 
t=-2) for the detection of screen relevant neoplasia. Results of single and double sampling 
were compared intra-individually and colonoscopy and histopathology were considered 
as gold standard. This study did not have the intention to determine the cut-off value 
with optimal sensitivity and specificity for screening. Instead, we evaluated whether a 
combination of sensitivity and specificity for double FIT sampling exists that is superior 
to single FIT sampling.
Figure 4.2 Study flow diagram of 1,589 subjects who participated in FIT sampling and 
subsequently underwent colonoscopy. ¹Incomplete colon evaluation in spite of possible 
additional evaluation by repeated colonoscopy, barium enema or virtual colonography. FIT, 
faecal immunochemical test; IBD, inflammatory bowel disease.
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Three different strategies for positive reading of double FIT sampling were used:
1. “one of two FITs+”: haemoglobin concentrations exceed the cut-off value 
in at least one out of two samples.
2. “two of two FITs+”: haemoglobin concentrations exceed the cut-off 
value in both samples.
3. “mean of two FITs+”: the geometric mean of haemoglobin concentrations 
from both samples exceeds the cut-off value.
Test sensitivities and specificities were assessed at cut-off values of 50, 75, 100, 150, and 
200 ng/ml. The Exact method was used to calculate 95% confidence intervals. Receiver 
operator curves (ROCs) for detecting screen relevant neoplasia were calculated for single 
FIT and all three strategies of double FIT sampling. In addition, sensitivities of all three 
strategies for double FIT sampling were compared to single FIT sampling at a specificity 
of 85%, 90% and 95% using McNemar’s test for correlated proportions. All analyses were 
performed with SPSS for Windows Version 15.0 (SPSS Inc., Chicago, USA).
RESULTS
Participants
Samples were returned by 1,589 patients, 493 of which were excluded from further analysis 
because of reasons listed in Figure 4.2. In 33 cases repeated colonoscopy or radiology 
was performed. Mean age of the participants included was 60, 0 years (range 19–91 yrs, 
SD 12.5) and 48% of the study cohort was male.
Table 4.1 shows the primary indications for colonoscopy in individuals eligible for analysis. 
In this cohort 59% (N=646) of individuals were referred for colonoscopy because of 
symptoms, whereas 37% (N=408) of subjects were referred for screening or surveillance 
colonoscopy. In 4% (N=42) of all individuals the indication remained unspecified.
Colonoscopy results
Colorectal cancer was found in 35 (3, 2%) of 1,096 included individuals. Malignancies were 
classified as stage I in 7 (20%), stage II in 13 (37%), stage III in 6 (17%) and stage IV in 3 
(9%) patients. Six rectal cancers (17%) could not be staged accurately due to the effects 
60
Double sampling of a Faecal Immunochemical TestChapter 4
of preoperative radiation. In 104 (9, 5%) individuals, one or more advanced adenomas 
were found. Consequently, screen relevant neoplasia were found in 124 (11, 3%) subjects.
Colorectal neoplasia detection and positivity rates
At a cut-off value of 50 ng/ml, the positivity rate of single FIT was 17%, resulting in 
detection of 91, 4% (32/35) of CRCs and 60, 6% (63/104) of all advanced adenomas 
found at colonoscopy. In subjects who tested negative for occult blood on single FIT, the 
additional FIT detected 2 more CRCs and 7 additional advanced adenomas. 
Positivity rates ranged from 17–10% (with increasing cut-off values) for single FIT, from 
22–12% for “one of two FITs+”, from 12–7% for “two of two FITs+”, and from 17–9% for 
“mean of two FITs+”.
Table 4.1 Primary indications for colonoscopy among 1,096 consecutive patients enrolled 
for evaluation of double FIT sampling
Indication group Indication for colonoscopy N
Symptomatic/suspect
Weight loss 11
Clinical suspicion of diverticulitis 7
Clinical suspicion of IBD 8
Abdominal pain 110
Anaemia 71
Hematochezia 156
Altered bowel habits 182
Clinical or radiological suspicion of CRC 25
Colonoscopy for polypectomy 21
Diarrhea 31
Constipation 24
Total 646
Screening and surveillance
Average risk 39
Familial history of CRC 111
Lynch syndrome 17
Polyp surveillance 196
Post CRC surveillance 45
Total 408
Other
Not specified/others 42
Grand total 1,096
FIT, faecal immunochemical test; IBD, infl ammatory bowel disease; CRC, colorectal cancer.
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Sensitivity and specificity of single and double FIT strategies
Performance characteristics of single FIT and different strategies of double FIT sampling 
for detecting screen relevant neoplasia, at different cut-off values, are shown in Table 4.2.
At each cut-off value, maximum sensitivity for screen relevant neoplasia was obtained 
with “one of two FITs+”. Compared to single FIT, the highest increase in sensitivity was 
obtained with “one of two FITs+” at either 50, 75 or 100 ng/ml (6.4% increase over single 
FIT). However, the confidence intervals of the sensitivity of single FIT and “one of two 
FITs+” overlapped, and the specificity of “one of two FITs+” (83.0, 87.4 and 89.8% at 50, 
75, and 100 ng/ml, respectively) was lower than for single FIT (88.2, 90.5, and 92.5% at 
50, 75, and 100 ng/ml, respectively).
At each cut-off value, maximum specificity was found with “two of two FITs+”. The 
highest specificity (97, 5%) of all double FIT strategies was observed for “two of two 
FITs+” at the highest cut-off value (200 ng/ml). However, “two of two FITs+” resulted in 
lower sensitivities than single FIT. Moreover, by using single FIT, comparable specificities 
as for “two of two FITs+” could be reached (up to 95%) by using higher cut-off values 
(see Table 4.2).
Test characteristics of double FIT sampling strategies were comparable to single FIT 
sampling at a different cut-off value. For example at 75 ng/ml, the sensitivity of “one of 
two FITs+” (52%) was higher than the sensitivity of single FIT (46%). However, when the 
cut-off value of single FIT was decreased to 50 ng/ml, sensitivity became 48% (CI 39–57) 
which is close to sensitivity of “one of two FITs+” (52%; CI 43–61). The accompanying 
specificity of single FIT at 50 ng/ml (88, 2%) was virtually equivalent to the specificity of 
“one of two FITs+” (87, 4%). As shown in Table 4.2, test characteristics of “mean of two 
FITs+” were comparable to single FIT.
Receiver operator curves
For single FIT and the three double FIT strategies, ROCs were constructed (see Figure 
4.3). Highest sensitivities were reached with “one of two FITs+” and “mean of two FITs+”, 
whereas the highest specificities were reached with “two of two FITs+”. For all double 
FIT strategies, ROCs and area under the curves (AUCs) either overlapped or were very 
close to each other (see Figure 4.3). Although the highest AUC was found for “mean of 
two FITs+”, all AUCs were within the 95% confidence interval of the AUC of single FIT.
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Comparison at fixed specificities
To evaluate to what extent an increase in sensitivity by double FIT sampling went at 
the cost of decreased specificity, single FIT and the three double FIT strategies were 
analyzed at equal specificities. Table 4.3 shows cut-off values and sensitivities at 85%, 
90% and 95% specificity, for each strategy. At any of these specificities, no strategy for 
double FIT sampling yielded a sensitivity that differed significantly from the sensitivity of 
single FIT.
Figure 4.2 ROC curves of single and double FIT sampling strategies for the detection of 
screen relevant neoplasia. FIT, faecal immunochemical test; “one of two FITs+”, at least one of 
both FITs above the cut-off value; “two of two FITs+”, both FITs above the cut-off value; “mean 
of two FITs+”, geometric mean of both FITs above the cut-off value; AUC, area under the curve; 
CI, confidence interval.
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Additional analysis
All analyses described above were repeated for the outcomes advanced adenomas and 
CRC. Results are shown in Supplementary Tables S4.1–S4.4 and Supplementary Figures 
S4.1 and S4.2. The results found were very similar to those for screen relevant neoplasia.
In total 251 cases were excluded because of an error in FIT sampling. The majority of 
155 cases was excluded as the date of sampling of one or both of the tests was unsure. 
These cases were included in additional analysis, to evaluate if exclusion of these cases 
would cause bias. As shown in the Additional file 1, the results of these analysis were 
similar. The remaining 96 sampling errors were due to sampling on or after the day of 
colonoscopy, performance of only one test, or failure in FIT analysis.
DISCUSSION
In the present study three different strategies of double FIT sampling were compared to 
single FIT sampling. In total, 1096 subjects were included and evaluated by colonoscopy. 
None of the double FIT strategies proved to have a superior combination of sensitivity 
and specificity compared to single FIT sampling, as is clear from the comparable ROCs 
and similar AUCs found for all strategies. When comparing sensitivities of single FIT and 
the three double FIT strategies at fixed specificities of 85%, 90% and 95%, no relevant 
differences were observed. In fact, at every level of specificity, a comparable sensitivity 
as observed for “one of two FITs+” could be obtained by single FIT by simply lowering 
the cut off value.
A priori expectations were that double FIT sampling would increase sensitivity, as this 
has been observed previously for g-FOBT and FIT.18,19,24 Accordingly, it was shown in the 
present study that the highest sensitivity was obtained for ‘’one of two FITs+’’. However, 
this strategy resulted in the lowest specificity.
Our findings are in line with a recent study in a population with an increased risk for CRC, 
in which AUCs for the highest out of one, two or three FITs did not differ.18 Although 
a direct comparison with a recent Italian screening study is difficult due to different 
methodology, the authors could also not find a clear superior performance of double 
over single FIT sampling either.15 Two other studies on double FIT sampling lacked 
calculation of direct sensitivity and specificity, as colonoscopy was not performed in FIT 
negative individuals.15,16 These characteristics are needed to determine how an increase in 
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sensitivity is counterbalanced by a decrease in specificity. Less recent studies did not use 
quantitative FITs or did not evaluate test characteristics at different cut-off values.17,20 In 
a recent study with a high CRC prevalence, average risk individuals sampled stool before 
screening colonoscopy. The authors found that the sensitivity increased and specificity 
decreased when a lower cut-off value or multiple tests were used. However, no comparison 
was made at an equal specificity. The AUCs for advanced neoplasia for one, two or three 
FITs did not differ.19 In the present study, the full potential of double FIT sampling was 
further studied by evaluation of several definitions of positivity. The present study adds 
important information as it is the first to determine if any of three strategies of double 
FIT sampling could increase sensitivity for screen relevant neoplasia, without substantially 
affecting specificity, at different cut-off values and in a colonoscopy controlled population.
A limitation of the present study is that not a screening population was tested but a referral 
population, partially containing high risk individuals. Therefore, test characteristics 
that depend on the prevalence of disease, i.e. positive and negative predictive values, 
cannot be generalized from this study to the screening population. However, the present 
study focused on sensitivity and specificity, test characteristics that are not influenced 
by the prevalence of the disease.25 Still, in this referral population, sensitivity may be 
overestimated and specificity underestimated due to work-up bias.26 This may occur as 
symptomatic participants have an increased likelihood for having both a positive FIT 
and a colorectal neoplasm. In particular, it should be noted that lower sensitivities for 
FIT in a screening population have been reported.19,27 On the other hand, we carried out 
a formal comparison of FIT results in CRC cases from a screening and referral cohort 
and found similar FIT results after correcting for tumour stage.28 Since for screening, only 
early stage cancers are relevant, in the present study late stage cancers were excluded from 
the analysis. Although possible differences in FIT results between referral populations, 
like in the present study, and screening populations cannot fully be excluded, the present 
study design still allows for comparing the sensitivities of different sampling schemes 
for FIT for early stage colorectal cancer. However, a complete correction of work-up bias 
cannot be ascertained. One should keep in mind that alternative study designs also have 
limitations like absence of a gold standard because no colonoscopies were performed, 
or in case colonoscopies were performed, relatively low numbers of cancers found.15,16,27 
In addition, in many studies different FITs, different endpoints (advanced adenoma, 
advanced neoplasia, screen relevant neoplasia), a different amount of cases, and a different 
selection of participants (e.g. subjects participating in colonoscopy screening) are used.
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To evaluate the effect of work-up bias, analyses were repeated after exclusion of subjects 
with rectal blood loss, anaemia and clinical suspicion of CRC (data not shown). Although 
the sensitivities for advanced adenomas found were 4.5–10% lower, our results were 
similar in the sense that double FIT sampling did not yield any superior combination of 
sensitivity and specificity compared to single FIT. For CRC data were similar, although 
too few cases remained to draw firm conclusions (data not shown).
In the current study the number of excluded participants was relatively high. This was 
mainly due to our stringent protocol on FIT sampling. Of the 251 individuals that were 
excluded from further analysis, in the majority of cases this was because date of sampling 
was not registered correctly on the FIT container, as described in the study protocol. 
Additional analysis including these cases showed similar results. The percentage of 
incomplete colonoscopies in the present study is in line with previous studies.7,29
According to our study protocol all FITs should be stored in the refrigerator close to the 
moment of handing in. In addition, both FITs are sampled maximum 72 hours prior to 
colonoscopy. As such, the time that the tests are at room temperature is kept as limited as 
possible. FITs kept at higher temperatures, are more susceptible to a decrease in sensitivity 
as a result of haemoglobin degradation. When compared to at least one of the screening 
studies7 this is still a relative short period of time. Therefore, only a slight decrease in 
haemoglobin concentration is to be expected.30
An important asset of the present study is the relatively high tumour yield, which allowed 
analyzing FIT performance for early and late stage CRC separately. As the potential health 
gain is highest for individuals with early stage cancer,31 this is relevant for population based 
screening programs. A second strength of this study is the fact that colonoscopy results were 
available for all participants, allowing the direct calculation of sensitivities and specificities.
CONCLUSION
In conclusion, this study strongly suggests that double FIT sampling, regardless of the 
definition of test positivity, does not provide a superior combination of sensitivity and 
specificity compared to single FIT sampling. Moreover, if it is aimed to increase sensitivity 
at the cost of specificity, this can be achieved equally well by lowering the cut-off value of 
single FIT sampling rather than by double FIT sampling. To what extent these findings 
pertain to the general population awaits confirmation in a screening setting.
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Hemorrhoids detected at colonoscopy: 
an infrequent cause of false-positive 
fecal immunochemical test results
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R.W.M. van der Hulst,  R.J. Loffeld, P. Scholten, A.C.T.M. Depla, A.A. Bouman, 
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ABSTRACT
Background: Colorectal cancer screening by fecal immunochemical tests (FITs) is 
hampered by frequent false-positive (FP) results and thereby the risk of complications 
and strain on colonoscopy capacity. Hemorrhoids might be a plausible cause of FP 
results. 
Objective: To determine the contribution of hemorrhoids to the frequency of FP 
FIT results. 
Design: Retrospective analysis from prospective cohort study. 
Setting: Five large teaching hospitals, including 1 academic hospital. 
Patients: All subjects scheduled for elective colonoscopy. 
Interventions: FIT before bowel preparation. 
Main outcome measurements: Frequency of FP FIT results in subjects with hemor-
rhoids as the only relevant abnormality compared with FP FIT results in subjects 
with no relevant abnormalities. Logistic regression analysis to determine colonic 
abnormalities influencing FP results. 
Results: In 2,855 patients, 434 had positive FIT results: 213 had advanced neoplasia, 
and 221 had FP results. In 9 individuals (4.1%; 95% CI, 1.4–6.8) with an FP FIT result, 
hemorrhoids were the only abnormality. In univariate unadjusted analysis, subjects 
with hemorrhoids as the only abnormality did not have more positive results (9/134; 
6.7%) compared with subjects without any abnormalities (43/886; 4.9%; P=.396). 
Logistic regression identified hemorrhoids, nonadvanced polyps, and a group of 
miscellaneous abnormalities, all significantly influencing false positivity. Of 1000 
subjects with hemorrhoids, 67 would have FP results, of whom 18 would have FP 
results because of hemorrhoids only.
Limitations: Potential underreporting of hemorrhoids; high-risk individuals. 
Conclusions: Hemorrhoids in individuals participating in colorectal cancer scree-
ning will probably not lead to a substantial number of false positive test results.
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BACKGROUND 
Colorectal cancer (CRC) ranks in top 3 of malignancyrelated mortality in Europe and 
the United States.1,2 Survival is closely related to stage of disease,3 and population-based 
screening is advocated in many countries. 
The screening strategy with the highest sensitivity for detection of colonic neoplastic 
lesions is high-quality screening colonoscopy. Yet, because screening colonoscopy 
has drawbacks including low participation rates and complications,4-7 others advocate 
preselection by fecal occult blood tests (FOBTs). In population-based screening by fecal 
immunochemical tests (FITs or immunochemical FOBTs), only participants with a 
positive test result require colonoscopy. However, in almost half of all screenees with a 
positive FIT result, no advanced neoplasia is found at colonoscopy.8,9 These false positive 
(FP) results could lead to unnecessary colonoscopy-related complications, futile strain on 
endoscopic resources, psychological stress for the screenee, and a decrease in confidence 
in the screening program. Therefore, the number of FP FIT results should be as low as 
possible.
Because of their natural history, hemorrhoids are a plausible explanation for (both visible 
and occult) rectal bleeding. Although still unknown, hemorrhoids may be an important 
explanation for FP FIT results. Therefore, the aim of this study was to determine the 
association between hemorrhoids and FIT results.
METHODS 
Study population
For this study, the data set that was used was selected from an ongoing study on FIT 
performance that was designed to answer several research questions.10-12 The data were 
collected between June 2006 and October 2009. In 5 medical centers in and around 
Amsterdam, the Netherlands, ambulatory subjects 18 years of age and older scheduled 
for elective colonoscopy were invited regardless of the indication for colonoscopy 
(screening, surveillance, or symptoms). Exclusion criteria used were no informed consent, 
hospitalization, age younger than 18 years, colostomy, total colectomy, colitis with ulcer(s), 
and a documented history or subsequent diagnosis of inflammatory bowel disease. The 
study was approved by the local medical ethics review board of each of the 5 hospitals.
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Study design
Participants were requested to perform at least 1 FIT 1 or 2 days before bowel preparation 
and colonoscopy. Eligible subjects were invited to participate by telephone. When 
interested, a detailed information package was sent by mail, containing a FIT, sampling 
instructions, and an informed consent form. If an individual could not be reached by 
telephone on multiple occasions, the same package was sent with an additional explanatory 
letter. The instructions indicated that contact of stool with water and urine should be 
prevented, and the tests should be kept refrigerated until transport to the hospital. The 
FIT was performed at maximum 72 hours before colonoscopy. All subjects who were 
requested to perform only 1 FIT performed the test 1 day before undergoing colonoscopy. 
For comparability, in participants who performed more than 1 FIT, only the FIT performed 
1 day before colonoscopy was selected for analysis in this study. 
The test used in this study is the automated OC-sensor (Eiken Chemical Co, Tokyo, 
Japan), which has a quantitative outcome. Completed FITs and informed consent forms 
were handed in at the endoscopy department on the day of the colonoscopy. All tests 
were frozen at -20°C on arrival. Two experienced technicians who were unaware of the 
clinical data analyzed all tests according to the manufacturer’s instructions. The OC sensor 
MICRO desktop analyzer (Eiken Chemical Co) was used for all analyses.13
Colonoscopy and histology
Experienced gastroenterologists performed or supervised all colonoscopies and were 
unaware of the FIT results. All participants were offered conscious sedation with 
midazolam. Assessment of bowel preparation was judged by the individual endoscopist. 
Colonoscopy was considered complete when the cecum was intubated with identification 
of the appendiceal orifice or the ileocecal valve. The presence of hemorrhoids was 
classified retrospectively as reported in the endoscopy report. When available, grading of 
hemorrhoids according to the degree of prolapse was scored.14 The size of polyps detected 
was estimated by the endoscopist by using biopsy forceps. 
All tissue samples obtained during colonoscopy were evaluated according to routine 
procedures. Adenomas with high-grade dysplasia, villous components, and/or at least 1 
cm in size were considered advanced adenomas.15 The presence of CRC and/or 1 or more 
advanced adenomas was classified as the presence of advanced neoplasia.
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Statistical analysis
The primary endpoints of this study were the prevalence of hemorrhoids in individuals 
with a positive FIT result and negative findings on colonoscopy (i.e., FP tests) and the 
relative frequency of FP test results in subjects with and without hemorrhoids. Multiple 
colonic abnormalities in 1 patient might influence test result positivity. The frequency of 
FP FIT results in subjects with hemorrhoids as the only abnormality was compared with 
the frequency of FP FIT results in subjects without any colonic abnormalities. Logistic 
regression analysis was used to study which colonic abnormalities are risk factors for 
FP FIT results.
Colonoscopy and histology were considered the criterion standard for the presence 
of advanced neoplasia and hemorrhoids. Subjects with an incomplete colonoscopy or 
insufficient bowel preparation were excluded from analyses unless CRC was found. 
Subjects with an incomplete colonoscopy were included in analyses if it was followed by 
a second complete colonoscopy within 6 months. Subjects with 1 or more polyps from 
which no material was obtained for histological examination (N=147) were excluded. This 
includes polyps that could not be retrieved after polypectomy or polyps that were not sent 
for histopathological evaluation because no clinical consequences of a histopathological 
diagnosis were anticipated (e.g., because of comorbidity). These subjects were excluded 
because it is unknown whether the polyp was an advanced adenoma and therefore 
whether the FIT result was true or  false positive/negative. In addition, subjects in whom 
the significance of hemorrhoids was uncertain were excluded (i.e., subjects in whom 
hemorrhoids reported were described as only 1 hemorrhoid or fibrotic hemorrhoids).
False positivity was defined as a FIT result of 50 ng or more of hemoglobin per milliliter 
of buffer solution and no advanced neoplasia (either advanced adenomas or CRC) at 
colonoscopy. All individuals with a FIT FP result were evaluated for the presence of 
different colonic abnormalities, particularly the frequency of hemorrhoids as the only 
abnormality detected.
To study the association between hemorrhoids and FP test results in more detail, only 
subjects without advanced neoplasia were selected. These subjects are by definition at 
risk of FP FIT results. The Fisher exact test was used to compare the number of FP test 
results in individuals with and without hemorrhoids. To avoid possible heterogeneity 
in occult blood loss caused by the presence of other abnormalities 2 additional groups 
were selected: (1) the group of subjects without any abnormalities at colonoscopy and 
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(2) the group of individuals in whom hemorrhoids were the only abnormality found at 
colonoscopy. Groups 1 and 2 were compared for the frequency of test FP results. Finally, 
logistic regression analysis was used to study the effect of different colonic risk factors 
that could influence FP FIT results. False positivity (FIT  50,  75, and  100 ng/mL) was 
used as a dependent variable and the presence of hemorrhoids, the presence of 1 or more 
diverticula, the presence of 1 or more nonadvanced polyps, and finally the presence of 
1 or more other abnormalities (i.e., abnormalities not included in the other variables) 
were independent variables. The variable other abnormalities was scored positive when 
abnormalities such as angioectasia, aphthous lesions, lymphoma, and lipoma, were 
present. In multivariate analysis, the influence of the these variables on false positivity 
was corrected for age and gender.
All analyses were performed with SPSS for Windows version 15.0 (SPSS Inc, Chicago, Ill).
RESULTS
Participants
In this study, 3,339 subjects underwent colonoscopy and performed an FIT. In 2,893 
individuals, a total colonoscopy was performed and histological analysis was complete 
when applicable (Figure 5.1). Thirty-eight subjects were excluded because the clinical 
relevance of the hemorrhoids that were reported was not clear. The main indication for 
colonoscopy was surveillance and screening in 1,021, the presence of symptoms in 1,712, 
and unspecified in 122 (Table 5.1). Of the 2,855 subjects included in the analysis, 434 (15%) 
had a positive FIT result (cut-off value of 50 ng/mL) and 371 (13%) had hemorrhoids. 
Of all individuals with hematochezia as the indication for colonoscopy, 44 (11%) had 
FP results. This accounts for 44 of 221 (20%) of all FP results. Of all individuals with 
polypectomy as the indication for colonoscopy, 4 (6%) had FP results. This accounts for 
4 of 221 (2%) of all FP results. These subjects were not excluded because the frequency 
of FP FIT results was studied in subjects with hemorrhoids as the only abnormality, 
irrespective of the indication for colonoscopy.
Table 5.2 shows the age and sex distribution of the total population and true and FP 
results.
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Figure 5.1 Study flow diagram. #No histology obtained: no material obtained for histological 
examination. This concerns polyps that could not be retrieved after polypectomy or polyps 
that were not sent for histopathological evaluation because no clinical consequences of a 
histopathological diagnosis were anticipated. *Percentage of total study population (2,855 
subjects). FIT, fecal immunochemical test.
Complete colonic and histological 
evaluaƟon
N = 2,893
Included for analyses
N = 2,855
Exclusion:
No Ɵssue obtained for histology:
N = 147
Complete colonoscopy:
N = 3,040
(includes 36 who had complete second 
colonoscopy)
Exclusion:
Incomplete colonoscopy or insuĸcient 
bowel cleansing: 
N = 299
Colonoscopy and FIT:
N = 3,339
Exclusion:
Unsure signiĮcance of hemorrhoids:
N = 38
True posiƟves
N = 213
(7.5%)*
No advanced neoplasia
N = 2,463
(86%)*
True negaƟves
N = 2,242
(78.5%)*
False posiƟves
N = 221
(7.7%)*
False negaƟves
N = 179
(6.3%)*
Advanced neoplasia
N = 392
(14%)*
FIT posiƟve
N = 434
(15%)
FIT negaƟve 
N = 2,421
(85%)
#
80
Hemorrhoids and false positive FITsChapter 5
FP results
The frequency of hemorrhoids and abnormalities other than hemorrhoids detected in FP 
result cases are shown in Figure 5.2. Of the positives, the results of 221 FITs (51%) were 
found to be FP (i.e., no advanced neoplasia was detected at colonoscopy) (Figure 5.1). In 
all cases of FP results, it was observed that in 4.1% (9/221; 95% CI, 1.4–6.8) hemorrhoids 
were the only colonic abnormality that could have caused a positive test result.
Hemorrhoids
As stated previously, in 371 of 2,855 (13%) subjects, hemorrhoids were detected at 
colonoscopy. The grade of hemorrhoids was reported in 43%. After retrospective 
reclassification according to the degree of prolapse into the anal canal,14 86% were classified 
as grade I, 10% as grade II, and 4% were unspecified. From the 2,463 participants without 
Table 5.1 Primary indications for colonoscopy among 2,855 consecutive patients included 
in a study of the influence of hemorrhoids on false-positive FIT results
Indication group Indication for colonoscopy N 
Symptomatic/suspect Weight loss 29
Clinical suspicion of diverticulitis 28
Clinical suspicion of IBD 23
Abdominal pain 388
Anemia 164
Hematochezia 403
Altered bowel habits 422
Clinical or radiological suspicion of CRC 47
Colonoscopy for polypectomy 64
Diarrhea                                                           93
Constipation 51
Total 1,712
Screening and surveillance Average risk 64
Familial history of CRC 362
Lynch syndrome 44
Polyp surveillance 404
Post-CRC surveillance 147
Total 1,021
Other Not specified/others 122
FIT, fecal immunochemical test; IBD, inflammatory bowel disease; CRC, colorectal cancer.
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advanced neoplasia, 339 (14%) were found to have hemorrhoids. In Table 5.2, the mean 
age and gender are presented for participants without advanced neoplasia and with 
(N=339) or without (N=2,124) hemorrhoids.
Subjects with and without hemorrhoids were compared for FP test results. The number 
of FP FIT results in all subjects with hemorrhoids (41/339; 12.1%) was significantly 
higher than the number of FP FIT results in all susceptible subjects without hemorrhoids 
(180/2124; 8.5%; P=.04; Table 5.3). Individuals with a FP FIT result with hemorrhoids 
were significantly older compared with individuals without hemorrhoids with FP results 
Table 5.2 Demographics of 2,855 subjects included in a study of the frequency of hemorrhoids 
as the cause of false-positive FIT results
Group N Age, y (SD) P-value Females, % P-value
Total population 2,855 59.5 (12.8) - 55 -
False positives 221 62.5 (12.2) <.001 49 .21
True positives 213 66.6 (9.9) - 43 -
Total group without advanced neoplasiaa 2,463 58.6 (12.9) - 56 -
Hemorrhoids presentb 339 60.0 (11.5) .03 53 .22
No hemorrhoidsb 2,124 58.4 (13.1) - 56 -
Only hemorrhoids present 134 56.8 (13.6) .004 62 .71
No abnormalities 886 53.2 (11.5) - 60 -
FIT, fecal immunochemical test; SD, standard deviation.
a Susceptible to false-positive results.
b Next to hemorrhoids, other abnormalities may be present.
Figure 5.2 Overview of abnormalities and their frequencies in 221 cases with a false-positive 
fecal immunochemical test result. Note: Due to rounding, percentages add up to 100.1%.
False posiƟve cases
N = 221
(100%)
No 
abnormaliƟes
N = 43 (19.5%)
CombinaƟon of 
abnormaliƟes
N = 82 (37.1%)
Other 
abnormaliƟes 
only
N = 12 (5.4%)
Non advanced 
polyps only
N = 43 (19.5%)
DiverƟcula only
N = 32 (14.5%)
Hemorrhoids 
only
N = 9 (4.1%)
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(mean age 60.0 vs 58.4 years, respectively; P=.03). In addition, a slight, not statistically 
significant, gender difference was observed (Table 5.2).
To exclude the potential confounding influence of age and the presence of more than 
1 type of abnormality, subjects in whom no abnormalities were found at colonoscopy 
(N=886), were compared with subjects in whom hemorrhoids were the only abnormality 
(N=134) detected (groups 1 and 2, respectively). As shown in Table 5.4, groups 1 and 
2 did differ, but not statistically significantly, in the frequency of FP FIT results (4.9% 
vs 6.7%, respectively; odds ratio [OR] 1.41; P=.396). However, the mean age in group 
1 was significantly lower (53.2 years vs 56.8 years, respectively; P=.004; Table 5.2), and 
some statistically nonsignificant gender differences were observed (P=.71). Because 
these findings might indicate that the absence of a significant difference was caused by 
confounding, logistic regression analysis was performed.
Logistic regression analysis
Logistic regression analysis was used to study which abnormalities contribute significantly 
to the probability of an FP FIT result. In the univariate analysis, age, gender, the presence 
of hemorrhoids, diverticula, nonadvanced polyps, and other abnormalities (including 
ulcers, angioectasia, aphthous lesions, moderate chronic inflammation, lipoma, and 
lymphoma) were all significantly associated with FP FIT results.
In multivariate analysis, risk factors for false positivity were corrected for age and gender. 
It was found that hemorrhoids (OR 1.45), nonadvanced polyps (OR 1.78), and other 
abnormalities (OR 2.17) influenced the probability of false positivity significantly. Table 
Table 5.3 Frequency of false-positive FIT results in subjects with and without hemorrhoids 
studied in 2,463 subjects without advanced neoplasia
Hemorrhoids, N (%)a No. hemorrhoids, N (%)a Total, N
FIT positive results 41 (12.1) 180 (8.5) 221
FIT negative results 298 (87.9) 1,944 (91.5) 2,242
Total 339 (100) 2,124 (100) 2,463
Fisher exact test: P=.04. Cut-off value for FIT results positivity is  ≥50 ng/mL.
FIT, fecal immunochemical test.
a Other colonic abnormalities may be present in both groups.
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5.5 shows the level of significance of the abnormalities and ORs for false positivity at the 
cut-off values 50, 75, and 100 ng/mL.
Risk of false positivity attributable to hemorrhoids
The risk of FP FIT results exclusively because of hemorrhoids is the difference in risk 
of FP results in subjects with hemorrhoids only and subjects without any abnormalities 
(6.7%–4.9%=1.8%). In other words, per 1,000 subjects with hemorrhoids only, 67 FP 
FIT results will be found, of which 18 are attributable to the presence of hemorrhoids.
DISCUSSION
In this study, a large prospective cohort was used to study the association between 
hemorrhoids and FP FIT results. In 4.1% of all FP test results, hemorrhoids were the 
only abnormality detected. After correction for gender, age, and other abnormalities with 
logistic regression analysis, it was shown that subjects in whom hemorrhoids were the 
only abnormality found at colonoscopy were found to have a slightly higher rate of FP 
FIT results. The absolute increase in the risk of false positivity is small, i.e., 1.8% (from 
4.9% to 6.7%) and not significant.
Based on the current data, the number of FP FIT results exclusively caused by hemorrhoids 
seems to be limited. The threshold of 50 ng/mL for positivity was chosen because the 
number of potential FP test results would be highest at this cut-off value. Because 
hemolysis is needed before FIT can detect globin, the likelihood of detecting occult blood 
Table 5.4 Frequency of false-positive FIT results in subjects with hemorrhoids detected as 
the only abnormality at colonoscopy and in subjects without any abnormalities at colonoscopy
Hemorrhoids only, N (%) No. abnormalities, N (%) Total, N
FIT positive results 9 (6.7) 43 (4.9) 52
FIT negative results 125 (93.3) 843 (95.1) 968
Total 134 (100) 886 (100) 1,020
Fisher exact test: P=.396. Cut-off value for FIT positivity is ≥ 50 ng/mL.
FIT, fecal immunochemical test.
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from hemorrhoids may be low because of their location. By choosing the lowest cut-off 
value, the chance of detecting hemorrhoidal bleeding would be optimal. The current 
findings seem to be in line with those of a previous study in which subjects with a positive 
FIT result were sent for colonoscopy.17 In this study, the positivity rate in subjects with 
and without hemorrhoids was found to be similar.17
The source of blood loss was not identified for all subjects with positive FIT results. By 
logistic regression analysis, it was shown that hemorrhoids, nonadvanced polyps, and 
other abnormalities all contribute to FP test results. In addition, at cut-off values of 75 
and 100 ng/mL, which are frequently used in screening,8,18 the ORs were similar. However, 
because of fewer subjects with an FP test result at a higher cut-off value, the standard 
error increased and consequently the level of significance of the associations decreased. 
In almost 5% of subjects with an FP FIT result, no colonic abnormalities were detected. 
Because the FIT used in this study detects human globin by specific antibodies, FP test 
results caused by dietary factors can be excluded.18 Because the epitope for the antibody 
reaction of this FIT is within globin, which is degraded through the digestive tract, the 
likelihood of a more proximally located cause of occult bleeding is low, but cannot be 
excluded.19 In addition, the suboptimal sensitivity of colonoscopy for small lesions such 
as small adenomas is a potential confounder here.7,20,21
In population-based screening, even a small percentage of FP test results would cause 
a large number of unnecessary referrals for colonoscopy. If the current results are 
extrapolated to a hypothetical screening situation, of all 1,000 subjects with hemorrhoids, 
67 FIT results would be FP. Of those FP results, 18 would be exclusively attributed to the 
presence hemorrhoids. This number could be higher or lower because the prevalence of 
hemorrhoids in this clinical population is likely to be different from that in average-risk 
individuals participating in a screening program. A recent study on colonoscopy screening 
participants in Austria found a prevalence of hemorrhoids of 39%.22 These individuals 
might, however, be different from participants in FOBT screening. Unfortunately, the 
true prevalence of hemorrhoids seems to remain a black box because other studies 
showed prevalences ranging from 4% to 86%, depending on the population studied and 
the methodology used.23,24 We still would expect that this referral population will have a 
higher prevalence of hemorrhoids (e.g., because of an older population and indications 
of rectal bleeding). In addition, because the sensitivity of colonoscopy for small lesions 
such as small adenomas is far from optimal,7,20,21 a portion of the FP results related to 
hemorrhoids only might actually be true positives because of 1 or a few missed small 
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advanced adenomas. However, in general, all potential screenees with an episode of rectal 
bleeding should contact their physician instead of performing a FIT.
For proper interpretation of these results, some limitations need to be discussed. First, 
underreporting of hemorrhoids by the endoscopist may have occurred. This might 
be attributed to less attention to hemorrhoids when significant other abnormalities 
were found or missing retroflexion of the colonoscope in the rectum. In addition, as 
description of the appearance of the anus was not a predefined reporting item, other 
sources of anorectal bleeding such as prolapse with anitis and rhagades may have been 
unreported. A future prospective study using standardized external anal inspection, 
rigid anoscopy, and flexible colonoscopy with retroflexion would be superior. Second, 
colonoscopy may not be the best diagnostic tool to assess the presence of hemorrhoids.25 
However, previous studies suggest the usefulness of flexible colonoscopy for grading of 
hemorrhoids because the red color, circumference, size, and degree of elevation of rectal 
columns were found to be associated with rectal bleeding.26,27 Third, caution should be 
taken with extrapolation of FP results from this study to the screening setting because 
subjects from a referral setting were tested, who might well have a higher prevalence and/
or different bleeding pattern of hemorrhoids.
The strengths of this study are evaluation of the association of hemorrhoids and the level 
of FP results of a frequently used FIT with a quantitative outcome. In addition, insight 
is gained into the number of subjects with hemorrhoids and a negative FIT result in a 
large sample size.
In conclusion, this study indicates that the number of FP results that can be attributed to 
hemorrhoids only is small. Therefore, the influence of hemorrhoids on the effectiveness 
of an FIT-based screening program is likely to be limited.
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ABSTRACT
Introduction: Faecal immunochemical tests (FITs) are commonly used in screening 
for colorectal cancer (CRC). Diagnostic accuracy of FIT seems to be different in males 
and females. This disparity could result in a different benefit from screening. The 
cause of this disparity and the effect of cut-off values is so far unknown. 
Aims & methods: Aim of the present study was to compare the sensitivity and 
specificity of a frequently used FIT between males and females. Data were used 
from a large prospective cohort study on FIT performance. All participants in this 
cohort sampled a FIT and underwent complete colonoscopy. Outcome variables were 
CRC and advanced adenomas. Areas under the Receiver Operating Characteristic 
curves (ROC curves) were calculated and compared between males and females. 
The influence of potential explanatory variables on the relation between sensitivity 
and gender was evaluated. 
Results: At all cut-off values, FITs were found to have a higher sensitivity (range 
for the difference; 13–23%) and a lower specificity (range 2–4%) for CRC in males 
compared to females. For advanced adenomas, no statistically significant differences 
in sensitivity and specificity were observed. ROCs for CRC and advanced adenomas 
were similar for both sexes, and equal combinations of sensitivity and specificity for 
both sexes could be achieved by adjusting the cut-off values. For CRC, the difference 
in sensitivity could not be explained by age or location of the tumour. Although FIT 
was more sensitive for left sided cancer, this could not explain the gender difference 
since the anatomical distribution of CRCs over the colon in males and females was 
similar.
Conclusion: With FIT males have a higher sensitivity and a lower specificity for 
CRC than females. However, as ROCs were similar, equal accuracy can be achieved 
by allowing different cut-off values for both sexes. Location and age do not explain 
the differences in sensitivity observed.
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INTRODUCTION 
Colorectal cancer (CRC) is a leading cause of cancer related death world wide.1 Early 
detection by population screening is the most realistic approach to reduce CRC-related 
death. Faecal immunochemical tests (FITs) are increasingly used as the primary screening 
test for CRC.2 
Recently, it was found that FITs have a higher sensitivity and lower specificity for 
advanced colorectal neoplasia in males compared to females.3 Although diagnostic 
accuracy of a screening test is just one of several factors determining uptake of a screening 
program, a difference in FIT characteristics between males and females could implicate 
disparities in the expected benefit from CRC screening. Such a difference may require 
tailored screening. So far, it remains to be resolved whether this difference e.g. reflects a 
dissimilarity in advanced neoplasia distribution or a difference in the age of onset of CRC. 
The aim of the present study is to investigate whether the sensitivity and specificity of a 
frequently used FIT for the detection of CRC and advanced adenomas differs between 
males and females, and whether this difference can be explained by age, location, number 
and size of neoplastic lesions. 
MATERIALS AND METHODS 
Study population
For the current analysis, data were used from an ongoing study program on FIT 
performance. This program aims to answer a number of research questions and has been 
previously described extensively.4-6 In short, individuals scheduled for elective colonoscopy 
in 5 participating medical centres were invited to participate and perform a FIT prior to 
colonoscopy. In addition to the exclusion criteria of these previous studies, individuals 
with an indication of visible rectal bleeding, anaemia or clinical suspicion of CRC were 
excluded from the analysis to minimize potential work-up bias. The study was approved 
by the local medical ethics review board of each of the 5 hospitals.
Study design
The test used was an automated quantitative FIT: OC-sensor ® (Eiken Chemical Co., Tokyo, 
Japan). One experienced technician performed the analyses while being unaware of the 
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clinical data. All tests were analyzed by using the OC sensor MICRO desktop analyzer 
(Eiken Chemical co, Tokyo, Japan).7 Haemoglobin concentrations of ≥50, ≥75, ≥100, 
and ≥200 ng/ml of buffer solution were taken as cut-off values. These concentrations 
correspond to respectively ≥10, ≥15, ≥20 and ≥40 milligram of haemoglobin per gram 
of faeces.
Colonoscopy and lesions
Experienced gastroenterologists performed or supervised all colonoscopies. The 
endoscopists were unaware of the FIT result, in order to prevent investigator bias. 
Conscious sedation by Midazolam was offered to all patients. 
A complete colonoscopy was defined as intubation of the caecum with identification of 
the appendiceal orifice or valvula Bauhini, or intubation up to an obstructing neoplasm. 
Quality control measures included documentation of colonic landmarks. Individuals in 
whom the bowel cleansing was insufficient and individuals in whom the colonoscopy 
remained incomplete were excluded from analysis. The right colon was defined as the 
proximal part of the colon including caecum, ascending colon, right (or hepatic) flexure 
and transverse colon. The left colon was defined as the distal part of the colon including 
left (or splenic) flexure, descending colon, sigmoid and rectum.8,9 In case of multiple 
neoplasia detected on colonoscopy, patients were classified based on the most advanced 
lesion found. 
Tissue samples obtained at colonoscopy were sent to the department of pathology and 
evaluated according to current standards. Adenomas ≥1.0 cm, adenomas with a villous 
component (i.e. tubulovillous or villous adenoma) or severe/high-grade dysplasia were 
classified as advanced adenomas.10,11
Statistical analysis
Using colonoscopy as the reference test, sensitivities and specificities of FIT were 
calculated for two definitions of colonoscopy outcome: (i) the presence of CRC and (ii) 
the presence of advanced adenoma. Sensitivity was defined as the proportion of positive 
test results in patients with the colonoscopy outcome under consideration. Specificity 
was calculated as the proportion of negative test results in patients with an outcome less 
severe than the outcome under consideration. 
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Sensitivity and specificity of FIT at different cut-off values were compared between males 
and females. Receiver Operating Curves (ROCs) were calculated for both sexes separately 
and the Areas Under the Curve (AUC) were used to compare accuracies. 
To study whether gender dissimilarities are a reflection of differences in age, location and 
size or number of neoplastic lesions, a stratified analysis of 2x2 tables was done, as well as 
a multivariate logistic regression analysis. Age was dichotomized into subjects <65 and 
65 or older. Location was divided in left and right sided lesions. The number of advanced 
adenomas was grouped as 1 or >1, and size was grouped <10 mm or ≥10 mm. Stratified 
analyses and the multivariate analysis were performed for a FIT cut-off value of 50 ng/
ml only. In the multivariate analysis, age was used as continuous variable. Subjects with 
CRC or advanced adenomas on both sides of the colon were excluded from these analyses.
All analyses were performed with SPSS for Windows Version 20 (SPSS Inc., Chicago, 
USA).
RESULTS
Participants
Between June 2006 and October 2010, 4,704 subjects returned a FIT and underwent 
colonoscopy. Of these, 1,682 were excluded for different reasons (see Figure 6.1), leaving 
3,022 participants for analysis. As the first colonoscopy was incomplete in 107 participants, 
a second colonoscopy, barium enema or CT-colonography was needed to complete the 
colonoscopic evaluation. The mean age of the participants was 59.7 years (range 19–91 
years, SD 12.6), and 45% was male. The indication for colonoscopy was evaluation of 
symptoms in 44% (1,331/3,022), screening or surveillance in 47% (1,412/3,022), and 
unspecified in 9% (279/3,022) (see Table 6.1).
Colonoscopy
In 2.3% of the included subjects, CRC was found (69/3,022) and in another 10.1% one 
or more advanced adenomas were detected (304/3,022; see Figure 6.1). From all subjects 
with CRC, 11.6% (8/69) also had one or more advanced adenomas. The distribution 
of CRC stages according to the TNM classification, is demonstrated in Figure 6.1. The 
T-stage (Tumour-stage) distribution found was; 16% (11/69) T1, 25% (17/69) T2, 33% 
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(23/69) T3 and 6% (4/69) T4. In 14 (20%) individuals with CRC, T-stage was unknown 
due to preoperative radiotherapy or was not determined because of disseminated disease 
at time of diagnosis. 
Figure 6.1 Study flow diagram. 
1 Incomplete colon evaluation in spite of possible additional evaluation by repeated colonoscopy, 
barium enema or virtual colonography within 6 months.
2 CRC stage remained unsure as these cases received pre-operative radiotherapy or due to 
disseminated disease exact classification remained unknown.
Complete colonic and histological 
evaluaƟon; inclusion in analysis:
N = 3,022
No Ɵssue obtained for histology: 204
Complete colonoscopy:
N = 3,226
Exclusion: 1,166
- IBD or ulceraƟve coliƟs: 253
- radiaƟon procƟƟs: 9
- colostomy: 21
- extended hemicolectomy: 1
- error in FIT sampling: 89
- rectal bleeding or anaemia: 793
FIT obtained from:
N = 4,704
Colonoscopy:
N = 3,538
Incomplete colon evaluaƟon: 312
- insuĸcient bowel cleaning1: 116 
- incomplete colonoscopy1: 196
CRC
N = 69
Advanced adenoma
N = 304
No or non advanced adenoma
N = 2,649
CRC stage I
N = 25
CRC stage II
N = 10
CRC stage III
N = 16
CRC stage IV
N = 9
CRC stage unsure2 
N = 9
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Positivity rates
For the total population, the FIT positivity rate was 12.3% at a cut-off level of 50 ng/ml. 
Males were found to have a higher positivity rate (15.3%) compared to females (9.8%, 
P<0.001). At 50 ng/ml, 88% (61/69) of all CRCs and 35% (106/304) of all advanced 
adenomas tested positive. The positivity rate decreased at increasing cut-off values, to 
6.8% at 200 ng/ml. 
Sensitivity and specificity
In the total study population, the sensitivity and specificity for CRC at a cut-off value 
of 50 ng/ml was 88% and 90% respectively. For advanced adenomas, these figures were 
35% and 92% respectively (see Tables 6.2 and 6.3). At all cut-off values, males were found 
to have a higher sensitivity for CRC than females. The difference in sensitivity ranged 
from 13% to 23% and was significant at the cut-offs 75 and 100 ng/ml. The specificity 
Table 6.1 Primary indication for colonoscopy among 3,022 consecutive patients included 
for analysis of FIT characteristics according to gender
Indication group Indication for colonoscopy N 
Symptomatic Weight loss 88
Clinical suspicion of diverticulitis 26
Clinical suspicion of IBD 40
Abdominal pain 355
Altered bowel habits 548
Clinical or radiological suspicion of CRC 54
Diarrhoea 128
Constipation 92
Total 1,331
Screening & surveillance Average risk 103
Familial history of CRC 482
Lynch syndrome 54
Polyp surveillance 578
Post CRC surveillance 195
Total 1,412
Other Not specified/others 279
Grand total 3,022
FIT, faecal immunochemical test; IBD, inflammatory bowel disease; CRC, colorectal cancer.
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for CRC was significantly lower in males compared to females, but the difference was 
small (between 2.2 and 3.9%). For advanced adenomas, the differences in sensitivity and 
specificity between males and females were small and mostly not significant (Table 6.3). 
Receiver Operator Curves (ROCs) 
The test characteristics for males and females at each cut-off value are visualised in the 
ROCs in Figures 6.2 and 6.3. The AUCs for CRC for males and females were 0.95 (95% 
CI 0.909–0.985) and 0.90 (95% CI 0.819–0.981) respectively. The ROCs and AUCs for 
advanced adenoma were very similar between males and females (see Figure 6.3).
Table 6.2 Comparison of sensitivity and specificity of a FIT for detection of CRC in males and 
females at different cut-off values
Sensitivity
FIT cut-off Total
N=69*
Males
N=45*
Females
N=24*
Difference P-value
50 ng/ml
(CI)
88.4%
(78–95)
93.3%
(82–99)
79.2%
(58–93)
14.1% 0.12
75 ng/ml
(CI)
85.5%
(75–93)
93.3%
(82–99)
70.8%
(49–87)
22.5% 0.03
100 ng/ml
(CI)
85.5%
(75–93)
93.3%
(82–99)
70.8%
(49–87)
22.5% 0.03
200 ng/ml
(CI)
75.4%
(64–85)
80.0%
(65–90)
66.7%
(45–84)
13.3% 0.25
Specificity
FIT cut-off Total
N=2,953#
Males
N=1,312#
Females
N=1,641#
Difference P-value
50 ng/ml
(CI)
89.5%
(88–91)
87.3%
(85–89)
91.2%
(90–93)
-3.9% <0.05
75 ng/ml
(CI)
91.5%
(90–95)
90.1%
(88–92)
92.6%
(91–94)
-2.5% <0.05
100 ng/ml
(CI)
92.6%
(92–94)
91.2%
(90–93)
93.7%
(92–95)
-2.5% <0.05
200 ng/ml
(CI)
94.8%
(94–96)
93.6%
(21–95)
95.8%
(95–97)
-2.2% <0.05
FIT, faecal immunochemical test; CRC, colorectal cancer; CI, confidence interval. 
* This concerns the total of subjects with CRC from which the sensitivity was calculated. # This concerns 
the total of subjects without CRC from which the specificity was calculated.
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The influence of potential explanatory variables
In patients with CRC, males were found to have a higher FIT positivity rate than females 
(93% vs 79%, P=0.08). This difference persisted when stratifying CRC by location (i.e. 
left versus right; 100% vs 88% and 79% vs 51%, respectively). Overall for males and 
females, left sided CRC was found to have a higher positivity rate (96%) than right 
sided CRC (71%, P<0.05). However, within males and females with CRC an equal 
proportion of cancers was left sided. In the multivariate analysis, location was significantly 
associated with FIT sensitivity for CRC (see Table 6.4), but the univariate odds ratio 
for gender (OR 3.7, 95% CI 0.8–17.0) was not substantially affected by the inclusion 
Table 6.3 Comparison of sensitivity and specificity of a FIT for detection of advanced 
adenomas in males and females at different cut-off values
Sensitivity
FIT cut-off Total
N=304*
Males
N=164*
Females
N=140*
 Difference P-value
50 ng/ml
(CI)
34.9%
(30–41)
36.6%
(39–45)
32.9%
(25–41)
3.7% 0.55
75 ng/ml
(CI)
30.9%
(26–37)
32.9%
(26–41)
28.6%
(21–37)
4.3% 0.46
100 ng/ml
(CI)
28.6%
(24–34)
31.7%
(25–39)
25.0%
(18–33)
6.7% 0.21
200 ng/ml
(CI)
21.1%
(17–26)
24.4%
(18–32)
17.1%
(11–24)
7.3% 0.16
Specificity
FIT cut-off Total
N=2,649#
Males
N=1,148#
Females
N=1,501#
Difference P-value
50 ng/ml
(CI)
92.3%
(91–93)
90.8%
(89–92)
93.4%
(92–95)
-2.6% <0.05
75 ng/ml
(CI)
94.0%
(93–95)
93.4%
(92–95)
94.5%
(93–96)
-1.1% 0.22
100 ng/ml
(CI)
95.0%
(94–96)
94.4%
(93–96)
95.5%
(94–97)
-1.1% 0.24
200 ng/ml
(CI)
96.6%
(96–97)
96.2%
(95–97)
97.0%
(96–98)
-0.8% 0.28
FIT, faecal immunochemical test; CI, confidence interval. 
* This concerns the total of subjects with advanced adenoma from which the sensitivity was calculated. # 
This concerns the total of subjects without CRC and without advanced adenomas from which the specificity 
was calculated.
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Figure 6.2 Receiver operator curve of FIT for detection of CRC. ROC, receiver operator curve; 
FIT, faecal immunochemical test; CRC, colorectal cancer; AUC, area under the curve.
Figure 6.3 Receiver operator curve of FIT for detection of advanced adenoma. ROC, receiver 
operator curve; FIT, faecal immunochemical test; AUC, area under the curve.
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of location (and age) in the analysis (OR 4.9, 95% CI 0.9–26.8). As such, the relation 
between gender and FIT sensitivity cannot be explained by either age or the location 
of CRC. 
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In people with advanced adenomas, males were found to have a slightly higher positivity 
rate than females (37% vs. 33%, n.s.). Left sided advanced adenomas were more frequently 
positive (38%) than right sided lesions (24%, P=0.02). Also, subjects with more than one 
advanced adenoma were found to have a higher FIT positivity rate (63%) than subjects with 
one advanced adenoma (27%, P<0.001). The same was found for subjects with an advanced 
adenoma >9 mm (45%) compared to advanced adenomas <10 mm (12%, P<0.001). 
Table 6.4 Level of significance and odds ratios for different variables used in a multivariate 
logistic regression model predicting sensitivity of a FIT at cut-off of 50 ng/ml for detection of CRC
CRC
Univariate model Multivariate model
OR
(95% CI)
P-value OR
(95% CI)
P-value
Gender 3.7 
(0.80–17.02)
0.10 4.9 
(0.89–26.83)
0.07
Age 1.0 
(0.94–1.10)
0.70 1.0
(0.91–1.11) 
0.90
Location 9.0 
(1.64–49.45)
<0.05 11.0
(1.79–67.36) 
<0.05
Number of cases included in the model: 68
FIT, faecal immunochemical test; CRC, colorectal cancer; OR, odds ratio; CI, confidence interval.
Table 6.5 Level of significance and odds ratios for different variables used in a multivariate 
logistic regression model predicting sensitivity of a FIT at cut-off of 50 ng/ml for detection of CRC
Advanced adenoma
Univariate model Multivariate model
OR (95% CI) P-value OR (95% CI) P-value
Gender 1.2 
(0.73–1.90)
0.50 0.9
(0.54–1.62)
0.82
Age 1.0 
(0.99–1.04)
0.27 1.0 
(0.98–1.04)
0.49
Location 2.0 
(1.34–3.11)
<0.05 1.4 
(0.84–2.33)
0.19
Adv adenoma size 6.1 
(2.87–12.79)
<0.05 5.7 
(2.60–12.30)
<0.05
Number of advanced adenomas 4.6
(2.50–8.44)
<0.05 4.0 
(1.95–8.16)
<0.05
Number of cases included in the model: 281
FIT, faecal immunochemical test; CRC, colorectal cancer; OR, odds ratio; CI, confidence interval.
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In males, a slightly higher proportion of advanced adenomas was right-sided (40% in 
males versus 32% in females), large in size (76% in males versus 71% in females), or 
consisted of multiple advanced adenomas (21% in males versus 17% in females). The 
distribution of these explanatory variables caused a shift in the OR for gender from 1.2 
in the univariate analysis to 0.9 in the multivariate analysis, but either way the relation 
remained non-significant (see Table 6.5). In conclusion, the size and the number of 
advanced adenomas were important predictors of FIT positivity in advanced adenomas, 
but gender was not.
DISCUSSION
In this study sensitivity and specificity of FIT was assessed in males and females in a large 
cohort of subjects referred for colonoscopy. FIT was found to be more sensitive and less 
specific for CRC in men than in women. The ROC analysis revealed similar AUCs for 
males and females and a similar accuracy can be reached by adjusting the cut-off value 
in females. The difference in sensitivity between the sexes, could not be explained by age 
or location or the lesion. The sensitivity of FIT for advanced adenomas was unrelated to 
gender but strongly related to size and the number of advanced adenomas.
In males, FIT was found to have 13–23% higher sensitivity for CRC than in females. 
Previous studies already suggested a difference in test performance for the detection of 
advanced neoplasia in males and females.3 To evaluate the relation between gender and 
FIT sensitivity for CRC, the influence of the potential explanatory variables ´location of 
colonic lesions´ and ´age of the participant´ was assessed. These variables were chosen 
because it is known that CRC develops earlier in the lifetime of a man then of a woman.12 
In addition, left sided neoplasia have a higher likelihood for a positive FIT.9,13
It is also known that females have a higher prevalence of right sided CRC.14 In multivariate 
analysis of the present study, location was significantly associated with FIT sensitivity for 
CRC, but the univariate odds ratio for gender was not substantially affected by the inclusion 
of location and age in the analysis. By stratified analysis of 2x2 tables, it was found that the 
observed relation between gender and FIT sensitivity for CRC could not be explained by 
either location or age. It can only be speculated on whether the gender difference is due 
to other confounders as e.g. tumour size or tumour biology (e.g. blood vessel density). 
Other authors hypothesized that the higher serum concentration of haemoglobin in male 
blood would cause higher FIT positivity when blood is lost in the colon.3 
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For advanced adenomas, no significant difference in sensitivity was found between the 
genders. In multivariate analysis and stratified 2x2 tables it was found that the number 
and size of lesions are predictive for test sensitivity. This last observation is in line with 
other studies that showed that the number and size of polyps influence test accuracy for 
detection of advanced adenomas.15
Currently, CRC-screening with preselection by means of FIT sampling is a one size 
fits all approach. Gender specific screening guidelines could be considered, in order to 
optimize the effectiveness of a screening program in both males and females.3,16 However, 
test accuracy is only one of the factors that determine the efficiency of a CRC screening 
programme, and participation of the target population in the screening programme is an 
important other factor. In the English and Scottish screening programmes, it was found 
that participation was higher in women and in older age groups.17,18 Moreover, in the 
present study, we found only a difference between males and females in FIT accuracy for 
CRC and not for advanced adenomas. The same sensitivity for CRC as in males could 
be reached by lowering the cut-off value in females. Presumably, prevalent cancers will 
be detected in the first screening round, after which the focus of screening will be to 
detect advanced adenomas. In the absence of a gender difference in the sensitivity for 
advanced adenomas, sex specific cut-off values in screening seem unnecessary. In addition, 
individualizing screening guidelines adds to the complexity of a screening programme and 
should only be adopted if the expected benefits are substantial. Individualized screening 
guidelines may confuse providers and consumers to the point of decreasing adherence.19 
The current study provides insight into the relation between gender and the diagnostic 
accuracy of FIT for detection of CRC and advanced adenomas. To the best of our knowledge, 
this is the first study to observe that gender specific differences in FIT sensitivity are only 
present in CRC and not in advanced adenomas. This difference can be easily overcome by 
adjusting the cut-off value. Each participant underwent complete colonoscopy regardless 
of FIT outcome. This enabled direct calculation of not only sensitivity but specificity as 
well. The high number of advanced colonic neoplasia in the referral population that was 
used, enabled us to stratify for CRC, which was not possible before.3 
For proper interpretation of the results, some limitations need to be discussed. Firstly, 
location of lesions was assessed by the endoscopists by recognition of colonic landmarks, 
which may limit the precision with which the location of the neoplastic lesions can be 
called. Furthermore, there may be other explanatory variables for FIT performance 
that were not included, like for instance the use of NSAIDs.9 Another limitation is that 
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we tested a referral population rather than a screening population. Consequently, it 
cannot be excluded that, even after exclusion of subjects with anaemia en hematochezia, 
sensitivity may be overestimated and specificity underestimated due to work-up bias.20 
This may occur as symptomatic participants have an increased likelihood for having both 
a positive FIT and a colorectal neoplasm. However, in a recent comparison of the current 
study cohort with a screening population, similar faecal immunochemical test results in 
screening and referral CRC were found.21 In addition, true screening populations may be 
biased with symptomatic subjects as well, as reported by two recent studies.22,23 
In conclusion, males were found to have a higher FIT sensitivity and a lower specificity 
for CRC compared to females. However, as ROCs are similar, equal characteristics can 
be achieved by allowing different cut-off values for both sexes. Location of CRC and age 
of the individuals are not responsible for the observed differences in sensitivity. Whether 
the difference is relevant in screening remains questionable. No significant difference in 
test accuracy for advanced adenomas was found between the sexes.
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ABSTRACT
Using a bioinformatics-based strategy, we set out to identify hypermethylated genes 
that could serve as biomarkers for early detection of colorectal cancer (CRC) in 
stool. In addition, the complementary value to a Fecal Immunochemical Test (FIT) 
was evaluated. Candidate genes were selected by applying cluster alignment and 
computational analysis of promoter regions to microarray-expression data of colo-
rectal adenomas and carcinomas. DNA methylation was measured by quantitative 
methylation-specific PCR on 34 normal colon mucosa, 71 advanced adenoma, and 
64 CRC tissues. The performance as biomarker was tested in whole stool samples 
from in total 193 subjects, including 19 with advanced adenoma and 66 with CRC. 
For a large proportion of these series, methylation data for GATA4 and OSMR were 
available for comparison. The complementary value to FIT was measured in stool 
subsamples from 92 subjects including 44 with advanced adenoma or CRC. Phosp-
hatase and Actin Regulator 3 (PHACTR3) was identified as a novel hypermethylated 
gene showing more than 70-fold increased DNA methylation levels in advanced 
neoplasia compared with normal colon mucosa. In a stool training set, PHACTR3 
methylation showed a sensitivity of 55% (95% CI: 33–75) for CRC and a specificity 
of 95% (95% CI: 87–98). In a stool validation set, sensitivity reached 66% (95% CI: 
50–79) for CRC and 32% (95% CI: 14–57) for advanced adenomas at a specificity of 
100% (95% CI: 86–100). Adding PHACTR3 methylation to FIT increased sensitivity 
for CRC up to 15%. PHACTR3 is a new hypermethylated gene in CRC with a good 
performance in stool DNA testing and has complementary value to FIT.
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INTRODUCTION 
Screening for colorectal cancer (CRC) is the most efficient strategy for reducing death from 
this devastating disease. Colonoscopy is the gold standard for the detection and removal 
of early lesions and is highly sensitive, but also invasive and costly.1,2 For population-wide 
screening simple and noninvasive procedures like stool testing are preferred.3 In follow-up 
to the guaiac-based Faecal Occult Blood Test (FOBT), the more sensitive immunochemical 
fecal occult blood test (Fecal Immunochemical Test or FIT4-6) is now widely used in 
screening programs in Europe and Japan, and is expected to reduce CRC mortality by 
around 30%.7 This test performance though, still leaves room for improvement which 
could come from molecular stool tests like those testing for tumor DNA in stool. 
Multiple assays have been developed and evaluated for this purpose, but sensitivities still 
remain suboptimal.8-14 The recently introduced combination of mutation markers with 
DNA methylation markers has yielded substantially improved test performance.13,15,16 
Methylation markers on their own, either alone or combined, have also yielded promising 
results, whereas the assays are technically less demanding.17-23 Methylation markers are 
appealing for CRC screening even more because DNA methylation is an early event in 
colorectal development, preceding chromosomal abnormalities, and mutations.24
Yet, the ultimate marker, or combinations of markers, for stool DNA testing still remains 
to be determined. To this end, in this study, we aimed to identify new hypermethylated 
genes in CRC by applying dedicated bioinformatics to microarray expression data of 
colorectal adenomas and carcinomas and to explore their potential in whole stool DNA 
testing for CRC.25,26 Furthermore, we set out to evaluate complementary value of such 
markers to FIT in a series of stool subsamples.
MATERIALS AND METHODS 
Cell line authentication
The CRC cell line HT29 was obtained from the American Type Culture Collection 
(LGC Standards GmbH). COLO205, Colo320, HCT 116, and RKO cell lines were kindly 
provided by Dr. G.J. Peters, Department of Oncology, VU University Medical Center, 
Amsterdam, the Netherlands. The method for authentication was by array comparative 
genomic hybridization (aCGH, 244 k Agilent oligonucleotide platform), conducted 
at the VU University Medical Center, Amsterdam, the Netherlands, most recently in 
110
PHACTR3 methylation as stool DNA testChapter 7
October 2008. The patterns of chromosomal changes observed were in concordance to 
the previously described chromosomal changes in these cell lines.27 LS513 was kindly 
provided by Dr. F. Praz, Centre de Recherche Saint-Antoine, Paris, France. Array CGH 
confirmed the genomic profile as described in literature (the Wellcome Trust Sanger 
Institute Cancer Genome Project web site28).
Strategy for methylation marker selection
The strategy used for identification and validation of new colon cancer-specific 
methylation markers included both bioinformatics analysis of microarray-based mRNA 
expression data and experimental validations of methylation levels as outlined in 
Supplementary Figure S7.1. First, genes downregulated in CRC compared with adenomas 
were subjected to a bioinformatics strategy for predicting cancer-specific methylation.25 In 
the experimental validation, the presence of DNA methylation was tested by methylation-
specific PCR (MSP) using the BioTrove OpenArray platform29 (BioTrove, Inc.), and high-
throughput LightCycler assays. Full details are provided in the Supplementary Methods.
Strategy for evaluating PHACTR3 methylation as a marker in CRC tissue 
and stool
Cell lines. For validating PHACTR3 methylation in CRC 2 different regions around the 
Transcription Start Site (TSS) were investigated for the presence of methylation in 6 CRC 
cell lines; regions -149 to -63 bp and +411 to +526 relative to the TSS. Next, HT29 and 
HCT116 cells were treated with 5-aza-20-deoxycytidine (5-AZA) to evaluate the effect 
of demethylation on mRNA expression.
Tissue. PHACTR3 methylation levels in the region +411 to +526 relative to the TSS and 
mRNA expression were measured in cancer and matched normal tissue samples from 9 
CRC patients by quantitative MSP and quantitative RT-PCR, respectively. Then, PHACTR3 
methylation levels were evaluated in an independent series of 34 normal colon mucosa 
tissue samples from cancer-free patients, 71 advanced adenomas, and 64 carcinomas. 
Finally, to evaluate the specificity of PHACTR3 hypermethylation for CRC, methylation 
levels in other tumor types were analyzed, being tumor tissue samples from 44 breast, 
20 cervix, 20 lung, 11 esophagus (5 adenocarcinomas and 6 squamous cell carcinomas), 
20 gliomas, 19 pancreas, and 15 stomach.
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Stool. To test the performance of PHACTR3 in a stool-based methylation test for CRC, a 
collection of 193 whole stool samples was split in a training set and a validation set of equal 
sizes. The training set consisted of a total of 100 stool samples, of which 66 from patients 
without colorectal neoplasia (58 healthy controls, 4 patients with colonic diverticula and 
4 patients with hemorrhoids), 9 from patients with hyperplastic polyps, 3 from patients 
with nonadvanced adenoma, and 22 from CRC patients. The training set was designed 
with more controls then cases, to better assess specificity. The validation set consisted 
of a total of 93 stool samples, 30 of which from healthy individuals, 19 from patients 
with advanced adenoma and 44 from CRC patients. The validation set contained more 
advanced neoplasia, including advanced adenomas, to better assess sensitivity. (Patient 
characteristics are described in Supplementary Table S7.3). In addition, methylation 
data for 2 other markers, that is, GATA4 and OSMR were available for comparison in 
95% of cases and 91% of controls from the training set and in all stool samples from the 
validation set tested for PHACTR3.18,20
Moreover, to examine the complementary value to FIT, an independent series of 92 
stool subsamples was analyzed for both FIT and PHACTR3 methylation. This stool 
series originated from a retrospective collection from referral subjects, and included 48 
stool samples from subjects without colon neoplasia, 24 from patients with advanced 
adenomas and 20 from patients with carcinomas. All details on tissue and stool collection, 
sample processing, and methodologies used, are presented in the Supplementary 
Methods.
Statistical analysis of DNA methylation in tissues and stool
Mean differences in methylation or mRNA expression levels in tissue samples were 
analyzed with the Mann–Whitney test or ANOVA. The relation between methylation 
levels in stool and the presence or absence of an advanced lesion was studied by receiver 
operator characteristic (ROC) analysis. The Area under the curve (AUC) was used as a 
measure of the test performance. CIs of proportions were calculated using the Wilson 
score method. To test whether age or gender were confounders in the relation between 
methylation levels and the presence or absence of a lesion, linear regression was used. 
For the combination of FIT and PHACTR3 methylation, we used a distribution-free 
rankbased method30 to calculate linear combination of the 2 markers giving highest 
diagnostic accuracy. Sensitivities were compared with FIT or PHACTR3 methylation 
alone at fixed specificities of 92%, 96%, and 98% using McNemar’s test. Calculations for 
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the combination of FIT and PHACTR3 methylation was carried out in the R package 
(version 2.8.1.). All other analyses were carried out using SPSS software (version 15.0; 
SPSS Inc.). Values of P≤0.05 were considered statistically significant.
RESULTS
Bioinformatics for discovery of candidate genes
Bioinformatics for discovery of candidate genes A total of 397 genes were downregulated 
in carcinomas compared with adenomas as determined by mRNA expression microarray 
analysis (Wilcoxon rank test P<1e–5 and Thas P<0.05; FDR<0.05).26 In 284 of these genes, 
a reported transcription start site (TSS) could be identified. These were subsequently 
subjected to a bioinformatics approach to predict cancer-specific methylation.25 This 
yielded 18 candidate genes, of which Phosphatase and actin regulator 3 (PHACTR3, 
NM_080672) was the only one that passed all further steps of experimental validation 
(see Supplementary Figure S7.1 and Supplementary Table S7.1).
PHACTR3 methylation and mRNA expression analysis in CRC cell lines 
and cancer and matched normal tissues
PHACTR3 harbors a dense CpG island located  -678 and +1,353 bp relative to the TSS 
(GC content: 65%, CpG(obs)/CpG(exp): 1.17). We designed conventional MSP primers 
in a region  -149 to  -63 bp and +411 to +526 relative to the TSS (see Supplementary 
Methods and Supplementary Figure S7.2). The region +411 to +526 relative to the TSS 
is located in exon 1 and is the same region as analyzed at the initial screen and validation 
of methylation status (see Supplementary Figure S7.1 and Supplementary Figure S7.2A). 
Of 6 cell lines tested, only HCT116 showed methylation in the region  -149 to - 63 bp 
relative to the TSS. For the region +411 to +526 relative to the TSS, methylation was 
found in all 6 cell lines tested (see Supplementary Figure S7.2). At the mRNA level these 
6 CRC cell lines only showed marginal PHACTR3 expression levels compared with the 
positive control (brain tissue; see Supplementary Figure S7.2). Treatment of HT29 and 
HCT116 with the demethylating agent 5-AZA resulted in reexpression of the gene (see 
Supplementary Figure S7.2), consistent with PHACTR3 expression being downregulated 
by methylation in these cell lines.
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Next, PHACTR3 methylation levels and mRNA expression were measured in cancer 
tissue and matched normal tissue from 9 CRC patients. All 9 CRC tissue samples showed 
significantly increased methylation levels compared with their normal counterparts. 
Although mRNA expression levels were low in both normal and tumor tissues, still in 6 
of 9 tumors PHACTR3 was significantly downregulated compared with expression levels 
in their normal counterparts (see Figure 7.1).
Figure 7.1 PHACTR3 methylation levels and mRNA expression in cancer and matched normal 
tissues. (A) PHACTR3 methylation levels in tumor (T) and matched normal (N) tissues from 9 
CRC patients. Quantifications represent mean methylation levels (error bars correspond to 
SD) relative to methylation levels in the normal tissues from 3 independent experiments. 
Methylation levels are calculated as [relative quantity of methylated PHACTR3/relative quantity 
of unmethylated Beta-actin (ACTB)] ratio x 1,000. Asterisks mark significant differences (P<0.05). 
(B) mRNA expression analysis of PHACTR3 by RT-PCR in tumor (T) and matched normal (N) tissues 
from 9 CRC patients. Quantifications represent mean expression values (error bars correspond to 
SD) relative to expression levels in the normal tissue from 3 independent experiments. Asterisks 
mark significant differences (P<0.05).
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PHACTR3 methylation analysis in colorectal advanced adenoma and 
carcinoma tissues
To confirm the differential levels of PHACTR3 methylation in CRC compared with 
normal mucosa, we tested an independent series of tissue samples and included a set 
of advanced adenomas as well. PHACTR3 methylation levels were 72-fold and 71-fold 
Figure 7.2 PHACTR3 methylation levels in tissue and stool. (A) PHACTR3 methylation levels 
in tissue samples of 34 normal colon mucosa, 71 advanced adenomas and 64 carcinomas 
(UICC stage I to IV). (B) PHACTR3 methylation levels in stool samples from 66 patients without 
colon neoplasia, 12 patients with hyperplastic polyps (HP) or nonadvanced adenoma and 22 
CRC patients (training set). Methylation levels are shown as relative quantity of methylated 
PHACTR3 x 1,000. (C) PHACTR3 methylation levels in stool samples from 30 patients without 
colon neoplasia, 19 patients with advanced adenomaand 44CRC patients (validation set). 
Methylation levels are shown as relative quantity of methylated PHACTR3 x 1,000. Box plots 
show first quartile, median, third quartile, and range of methylation levels. Dots represent 
individual data points, asterisks represent extremes.
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higher in advanced adenoma and carcinoma samples, respectively, compared with 
normal mucosa samples (see Figure 7.2A, P<0.01). ROC analysis yielded an AUC of 
0.93 (95% CI: 0.87–0.98) for CRC and 0.95 (95% CI: 0.93–0.98, see Figure 7.3A) for 
advanced neoplasia (advanced adenomas and carcinomas; see Figure 7.3). When fixing 
the cut-off for specificity at 100%, 72% of CRC and 81% of advanced neoplasia could 
be discriminated from normal mucosa. No significant differences in methylation levels 
were observed between advanced adenoma and carcinoma tissue samples or between 
carcinomas of different UICC stages (P=0.5 and P=.07, respectively). Age or gender was 
no confounding factors (P=0.1 and P=0.9, respectively). Methylation levels in other tumor 
types showed high levels of methylation in tissue samples from tumors of the intestinal 
tract (pancreatic, gastric, and esophageal cancer) and in cervical cancer, whereas lower 
levels of methylation were seen in cancers of lung and bladder, and little or no methylation 
was seen in cancers of breast, prostate, and brain (glioma; Supplementary Figure S7.3).
Sensitivity and specificity of PHACTR3 methylation in stool for detecting 
colorectal cancer
To investigate the performance of PHACTR3 methylation as a biomarker for CRC 
detection in stool, we measured methylation levels in 2 independent series of stool-
derived DNA samples (see Figure 7.2B and C). A training set was used to determine 
the optimal cut-off to detect CRC patients compared with controls and nonadvanced 
adenoma patients. The validation set was used to validate the results from the training 
set and to test the detection rate of advanced adenomas.
Training set. The training set consisted of 100 stool samples from individuals who all 
had undergone complete colonoscopy. ROC analysis of CRC (N=22) compared with 
nonadvanced adenomas and control samples (N=78) yielded an AUC of 0.77 (95% CI: 
0.64–0.90, see Figure 7.3B). Maximum sensitivity at a fixed specificity of 95% (95% CI: 
87–98) was reached at a cut-off value of 82.5 relative copies. At that cut-off, sensitivity 
was 55% (95% CI: 33–75) for detecting CRC.
Validation set. The validation set consisted of 93 stool samples from individuals who 
all had undergone complete colonoscopy. ROC analysis with advanced neoplasia (44 
CRC and 19 advanced adenoma) compared with healthy controls (N=30) resulted in 
an AUC of 0.83 (95% CI: 0.75–0.91, see Figure 7.3C). Using a cut-off of value of 82.5 
relative copies as defined with the training set yielded a specificity of 100% (95% CI: 
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Figure 7.3 Receiver operator characteristic analysis of PHACTR3 methylation in tissue and 
stool. (A) ROC curves of tissue samples. Sensitivity and specificity at various cutoff values of 
PHACTR3 methylation in tissue samples from 64 carcinomas versus 34 normal colon mucosas 
(left) and 135 advanced neoplasia versus 34 normal colon mucosas (right). The areas under the 
curves are 0.93 and 0.95, respectively. (B) ROC curves of stool samples (training set). Sensitivity 
and specificity at various cutoff values of whole stool samples from 22 CRC patients versus 66 
control patients without colon neoplasia (left) and 22 CRC patients versus 78 control patients (66 
patients without colon neoplasia and 12 patients with hyperplastic polyps (HP) or nonadvanced 
adenoma; right). The areas under the curves are 0.78 and 0.77, respectively. (C) ROC curves of 
stool samples (validation set). Sensitivity and specificity at various cutoff values of whole stool 
samples from 44 CRC patients versus 30 control patients without colon neoplasia (left) and 63 
patients with advanced neoplasia versus 30 control patients without colon neoplasia (right). 
The areas under the curves are 0.87 and 0.83, respectively. The solid line represents the ROC 
curve, the dashed line shows the reference line of no discrimination.
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86–100), a sensitivity of 66% (95% CI: 50–79) to detect CRC, and a sensitivity of 32% 
(95% CI: 14–57) to detect advanced adenomas. Using a cut-off of 28 relative copies, 
the highest possible sensitivity for advanced adenomas was 53% (95% CI: 32–73), at a 
specificity of 93% (95% CI: 79–98). Age or gender was no confounding factor (P=1.0 
and P=0.4, respectively).
Performance of PHACTR3 in comparison with other stool methylation 
markers
To compare the test performance of PHACTR3 methylation to other stool methylation 
markers, detection rates were compared with those obtained with the previously published 
markers, GATA418 and OSMR,20 which were tested by QMSP in a large proportion of 
the current training and validation series of stool samples. With the stool training set, 
the cut-offs for GATA4 and OSMR were determined to detect CRC at equal specificities 
as PHACTR3. Table 7.1 shows the AUC, the cut-offs, sensitivities and specificities of 
these 3 markers. Compared with OSMR, in the training set, PHACTR3 showed a higher 
AUC and sensitivity (52% vs. 29%) for carcinomas, and in the validation set PHACTR3 
showed a higher sensitivity for both advanced adenomas (32% vs. 21%) and carcinomas 
(66% vs. 43%) with higher specificity (100% vs. 90%). PHACTR3 and GATA4 showed 
equal AUCs and comparable sensitivities (52% vs. 57%) for detecting carcinomas in 
the training set. In the validation set, PHACTR3 showed a higher sensitivity for both 
Figure 7.3 Continued.
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advanced adenomas (32% vs. 16%) and carcinomas (66% vs. 39%) than GATA4, with 
higher specificity (100% vs. 93%).
The combination of these 3 markers, calling positive when at least 1 of the 3 markers 
would be positive, increased the sensitivity to detect advanced adenoma from 32% to 
42% and the sensitivity to detect carcinoma from 52% to 62% (training set) and from 
66% to 68% (validation set), however, at cost of specificity (decreased from 94% to 87% 
and from 100% to 83% for the training and validation set, respectively).
Combination of FIT and PHACTR3 methylation in stool
To investigate whether FIT and PHACTR3 methylation would have complementary value 
for detecting colorectal cancer and advanced neoplasia, both tests were evaluated in an 
independent series of stool subsamples. Because for DNA methylation analysis, the stool 
subsamples were processed in a different way compared with whole stool samples, different 
cut-offs were used, based on ROC analysis, to determine sensitivity and specificity (see 
Supplementary Methods). The sensitivities to detect advanced adenomas were 21% (5/24, 
95% CI: 9–40) for PHACTR3 and 21% (5/24, 95% CI: 9–40) for FIT. Combining PHACTR3 
with FIT, meaning positive for at least 1 of the 2 measurements, increased the sensitivity 
to 33% (7/24, 95% CI: 18–53). The sensitivities to detect CRC were 50% (10/20, 95% CI: 
30–70) for PHACTR3 and 65% (13/20, 95% CI: 43–82) for FIT. Combining PHACTR3 
with FIT increased the sensitivity to 95% (19/20, 95% CI: 76–99). The specificity of the 
Table 7.1 Test performances of PHACTR3, GATA4, and OSMR
  PHACTR3 GATA4 OSMR
Training set
AUC (95% CI) 0.76 (0.62–0.89) 0.76 (0.62–0.90) 0.60 (0.45–0.75)
Cut-off 82.5 16.5 3.6
Sensitivity CRC (N=21) 52% 57% 29%
Specificity (N=71) 94% 94% 94%
Validation set
Cut-off 82.5 16.5 3.6
Sensitivity AA (N=19) 32% 16% 21%
Sensitivity CRC (N=44) 66% 39% 43%
Specificity (N=30) 100% 93% 90%
AA, Advanced adenoma; GATA4, GATA-binding protein 4; OSMR, oncostatin M receptor.
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combination remained high [94% (45/48, 95% CI: 83–98) compared with 96% (47/48, 
95% CI: 86–99) for PHACTR3 alone and 98% (47/48, 95% CI: 89–100) for FIT alone]. In 
addition, a positive test for both FIT and PHACTR3, occurring in 7 of the 44 advanced 
neoplasia cases (see Supplementary Figure S7.4), revealed 100% specificity.
To evaluate whether the sensitivity of the combination of FIT and PHACTR3 was 
significantly higher than the sensitivity of either FIT or PHACTR3 methylation alone, we 
compared the sensitivities at equal specificity of 92%, 96%, and 98% (see Supplementary 
Methods). ROC analysis resulted in an AUC of 0.97 (95% CI: 0.93–1.0) for CRC and 0.79 
(95% CI: 0.69–0.92) for advanced neoplasia (see Figure 7.4), with sensitivity/specificity 
combinations of 61%/92%, 55%/96%, and 48%/98% (see Table 7.2 for advanced adenoma 
and cancer separately). At these specificities, sensitivities for detecting CRC increased 
up to 15% using the combination of FIT and PHACTR3 methylation compared with FIT 
alone, although statistical significance was not reached.
Figure 7.4 Receiver operator characteristic analysis of FIT and PHACTR3 methylation in stool. 
(A) sensitivity and specificity at various cutoff values of stool subsamples from 20CRC patients 
versus 48 control patients without colon neoplasia for FIT, PHACTR3 methylation and for the 
combination of both tests. The areas under the curves are 0.92, 0.77, and 0.97, respectively. 
(B) sensitivity and specificity at various cutoff values of partial stool samples from 44 patients 
with advanced neoplasia versus 48 control patients without colon neoplasia for FIT, PHACTR3 
methylation and for the combination of both tests. “A” represents the ROC curve for PHACTR3 
methylation only, “B” represents the ROC curve for FIT only, “C” represents the ROC curve for 
the combination of FIT and PHACTR3 methylation. The areas under the curves are 0.76, 0.68, 
and 0.79, respectively.
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DISCUSSION
Stool-based DNA testing is an appealing approach for noninvasive early detection of 
CRC. Both DNA mutations and DNA promoter hypermethylation have been investigated 
as targets of potential screening assays, and especially panels of markers have shown 
promising performance in initial studies. In this study, we applied a bioinformatics 
approach for identifying novel hypermethylated genes in CRC. This resulted in the 
identification of PHACTR3 as a new hypermethylated gene in CRC, which showed to 
have complementary diagnostic power to FIT in a pilot series. 
PHACTR3 was first described in 2003 as a protein associated with the nuclear scaffold 
in human promyelocytic HL-60 leukemia cells. It was found to bind to actin and to 
the catalytic subunit of Protein Phosphatase 1 (PP1), thereby inhibiting the function 
of PP1,31 which in turn can trigger apoptosis and can inhibit oncogenic signaling due 
to its interaction with pRb.32 Induced expression of PHACTR3 in HeLa cervical cancer 
cells stimulated cell spreading and motility.33 Finally, in a small study of non–small cell 
lung cancer patients gene mutations were found in 6/20 patients, which was associated 
with shortened overall survival.34 Yet, looking at PHACTR3 mRNA expression, abundant 
expression has been found in adult normal human brain and to a lesser extent in ovary, 
but not in other organs.31 Accordingly, in this study, we observed high PHACTR3 mRNA 
expression in human brain tissue, but much lower expression levels in normal colon 
tissues and again even lower expression in 6 of 9 matched tumor tissues. Although 
PHACTR3 showed high methylation levels in these 6 tumor tissue samples, methylation 
levels were equally high in the 3 tumor tissues from patients in which mRNA expression 
was not decreased compared with their normal counterparts. In addition, a direct 
correlation between the level of methylation and level ofmRNA expression in all 9 
tumor tissues could not be shown (Pearson correlation of  -0.3, P=0.5, data not shown). 
Treatment of HT29 and HCT116 cells with the demethylating agent 5-aza did result 
in reexpression of PHACTR3, however, consistent with the recent observation that 
methylation in the region of the first exon, which is the case for PHACTR3, is tightly 
linked to transcriptional silencing.35 Yet, the possibility that the observed reexpression 
of PHACTR3 could be secondary to demethylation of another gene or locus then 
PHACTR3 itself cannot be excluded. Although a direct relationship between PHACTR3 
hypermethylation and silencing of expression in CRC remains to be established, the fact 
that PHACTR3 methylation is highly associated with cancer still makes it an interesting 
candidate biomarker.
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Levels of PHACTR3 methylation in CRC tissues were prominently high and could 
significantly discriminate advanced adenoma and carcinoma from normal mucosa at the 
tissue level. High methylation levels are important for obtaining a good signal to noise 
ratio in a stool-based assay, especially when lesions to be detected are small. Interestingly, 
advanced adenoma tissue samples showed methylation levels as high as carcinoma tissues, 
making PHACTR3 methylation attractive as a biomarker, in compliance with recent 
guidelines which have stated that the detection of advanced adenomas and not only early 
carcinoma should be the goal of CRC screening.36
When further exploring its potential as a biomarker, in whole stool samples a sensitivity of 
55% to 66% for detecting CRC and a sensitivity of 32% for detecting advanced adenoma 
was observed at a specificity of 95% to 100%. The test performance of PHACTR3 can 
be further improved, which is illustrated by the higher AUC in tissues compared with 
stool, in particular the sensitivity to detect advanced adenomas. With the currently 
used method higher sensitivities could also be reached, however, at cost of specificity. 
The highest sensitivity that could be reached to detect advanced adenomas for example 
was 53%, resulting in a specificity of 93%. With these test performances, PHACTR3 
methylation is one of the best performing single methylation markers described so far.14 
Also in comparison to 2 previously published stool methylation markers GATA4 and 
OSMR, PHACTR3 showed superior test performance.
A strategy to improve test performance is to combine multiple markers in a single assay. 
Especially the high specificity makes PHACTR3 attractive as a marker for such a panel that 
would have increased sensitivity without major effects on specificity. The combination 
of PHACTR3 with GATA4 and OSMR in this study indeed did increase sensitivity, but 
at cost of specificity, which mainly is due to the lower individual specificities of GATA4 
and OSMR. Nevertheless, it will be difficult to reach 100% sensitivity with methylation 
markers only, because a portion of CRCs have no or low frequencies of methylated genes, 
the so-called CpG Island Methylator Phenotype (CIMP)-negative tumors.37 Therefore, 
an attractive alternative could be to combine methylation markers with a completely 
different marker like FIT. Because FIT is already being used in several screening programs 
throughout the world and logistics have already been put in place, adding a DNA 
methylation marker would be relatively easy. We therefore carried out a pilot study on 
the performance of PHACTR3 methylation in combination with FIT. The combination 
of FIT and PHACTR3 methylation increased the sensitivity for advanced neoplasia, 
that is, adenomas and CRC taken together, while maintaining a high specificity. These 
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experiments were done in a series of stool subsamples, which would be a good alternative 
for whole stool samples concerning logistics, stool processing, and storage of samples 
in large-scale screening programs. Because these stool subsamples were processed in a 
different manner compared with the whole stool samples described above, systematic 
differences exist when comparing these results to those from whole stool samples.4 
Still, the results obtained show the power of combining FIT with a DNA methylation 
marker. This is in line with recent findings that showed an improved test performance 
of combining other molecular markers (i.e., APC, BAT26, and long-DNA) with FOBT.12,38 
In conclusion, using a bioinformatics approach, PHACTR3 was identified as a new 
hypermethylated gene in CRC. Although we could not unravel the functional effect of 
PHACTR3 hypermethylation in CRC, we clearly showed its high potential as a biomarker 
in stool-based DNA testing. Furthermore, this study suggests that combining PHACTR3 
methylation with FIT could be particularly promising. The full potential of this marker 
or its combination with FIT awaits validation in a larger, well-controlled cohort study to 
test its performance in an asymptomatic population.
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SUPPLEMENTARY METHODS
Bioinformatic strategy for methylation marker selection
In the bioinformatics phase, first, genome-wide microarray based mRNA expression 
data of 37 colorectal adenomas and 31 adenocarcinomas were analyzed, as described by 
Carvalho et al.1 (GEO accession number GSE8067). Since promoter hypermethylation 
can influence gene expression by reducing or silencing transcription, we focused on genes 
downregulated in CRC compared to adenomas. Reason for this is that most colorectal 
adenomas never progress to cancer (~95%),2 and in order to find markers that are specific 
for high risk lesions, it makes sense to focus on those molecular alterations that take 
place during adenoma to carcinoma progression. Genes were selected based on median 
expression values and considered as differentially downregulated when a Wilcoxon 
Rank p-value <1e-5, or a Thas1 p-value <0.05 corresponding to a FDR <0.05. Then, 
from these genes, those with a reported transcription start site (TSS) were subjected to 
a bioinformatics approach to select genes with a high potential to be methylated using 
BROAD and DEEP analysis, as described before.3
OpenArrayTM and Lightcycler® experiments
A first screen for the presence of methylation was done by methylation specific PCR 
(MSP) on a BioTrove OpenArrayTM platform4 (BioTrove, Inc. Woburn, MA, USA) on 
83 normal mucosa and 80 carcinoma tissues. Whenever possible, we designed primers 
covering different transcript variants. MSP reactions were performed in 33 nL reactions 
based on SYBR® Green I chemistry. A sample was considered to be methylated if the 
Ct value was less than 42 and Tm fell within an automatically derived marker-specific 
Tm interval (personal communication Wim van Criekinge). To validate the presence of 
methylation, we selected genes that were methylated in >25% of CRC samples and in 
<15% of normal mucosa samples (see Supplementary Table S7.1). Two genes, Fucokinase 
(FUK, NM_145059) and Phosphatase and actin regulator 3 (PHACTR3, NM_080672), met 
these criteria and presence of methylation was validated by means of high through-put 
LightCycler MSP in a subset of the series used for OpenArrayTM experiments, consisting 
of 48 normal mucosa and 42 CRC tissues samples. MSP reactions on the LightCycler® 
were based on SYBR® Green I chemistry using a total reaction volume of 10 μl. Further 
analysis of FUK was hampered by technical issues. For PHACTR3 we were able to create 
robust MSP assays to study the methylation status in more detail.
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Cell lines
All CRC cell lines (HT29, COLO205, Colo320, HCT 116, RKO, and LS513) were cultured 
under standard conditions in Dulbecco’s modified Eagle’s medium (DMEM; BioWitthaker, 
Lonza, Verviers, Belgium) supplemented with 10% fetal calf serum, 100 U/ml penicillin 
(Astellas Pharma BV, Leiderdorp, The Netherlands), 100 g/L streptomycin (FisioPharma, 
Palomonte, Italy), and 2 mmol/L Lglutamine. To investigate re-expression of PHACTR3 
after inhibition of DNA methyltransferases and HT29 and HCT116 cells were treated 
with 1 μM 5-aza-2’-deoxycytidine (5-AZA; Sigma Chemical Co., St. Louis, MO, USA) 
for 3 days.
Tissue samples and DNA isolation
Tissues from 34 normal colon mucosa from cancer-free patients, 71 advanced colon 
adenomas and 64 colon carcinomas were collected from the tissue archive of the 
department of pathology at the VU University medical center, Amsterdam, The 
Netherlands (for patient characteristics, see Supplementary Table S7.2). Adenomas were 
defined as advanced when ≥10 mm, harboring any villous features (i.e. tubulovillous 
or villous adenoma) and/or high-grade dysplasia. DNA from formalin-fixed paraffin-
embedded (FFPE) was extracted by a column-based method (QIAamp DNA micro kit, 
Qiagen, Hilden, Germany) as described before.5,6 DNA from snap-frozen tissues was 
isolated using TRIzol (Invitrogen, Breda, NL) following the supplier’s instructions. DNA 
was quantified using the Nanodrop 1000 UV spectrophotometer (Nanodrop Technologies 
Inc, Wilmington, DE, USA). In addition, independent series of FFPE tissues were 
collected from the tissue archive from the University Hospital Liège, Belgium and from 
the Maastricht University Medical Center, The Netherlands. All samples were used in 
compliance with the institutional regulations for use of patient material. DNA was isolated 
from 9 CRC tissues and matched distant normal colon tissues, from 163 independent 
colon tissues [83 normal colon mucosas (41 from cancer-free patients and 42 from 
resection margins from CRC patients) and 80 CRCs], and from cancer tissues of other 
origin [44 breast, 20 cervix, 20 lung, 11 esophagus (5 adenocarcinomas and 6 squamous 
cell carcinomas), 20 gliomas, 19 pancreas and 15 stomach]. Per sample 15 sections of 
10μm were deparaffinized and DNA extraction was performed using phenol/chloroform 
extraction and resuspended in 80 μl of LoTE (3 mmol/L Tris, 0.2 mmol/L EDTA, pH 8.0). 
DNA was quantified using the PicoGreen dsDNA quantitation kit (Molecular Probes, 
Invitrogen, CA, USA).
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Stool samples and DNA isolation
Whole stool samples
Whole stool samples from subjects with either no colon neoplasia, hyperplastic polyps, or 
(advanced) adenomas were collected from subjects over 50 years of age who underwent 
primary colonoscopy screening for CRC within the framework of a workplace-based 
community colorectal cancer study at the Maastricht University Medical Center and 
from referral subjects who underwent colonoscopy at the VU University Medical Center 
in Amsterdam. Stool samples from colonoscopy-confirmed CRC patients who were 
diagnosed with all stages of CRC were collected at the VU University Medical Center in 
Amsterdam and from a multicenter prospective trial in Germany, in compliance with the 
institutional ethical regulations. All stool samples were collected prior to colonoscopy 
and before the start of laxative treatment preceding colonoscopy. All colonoscopies were 
performed or supervised by experienced endoscopists. Stool stabilization buffer was 
added to the stool sample by the subject immediately after defecation (Exact Sciences, 
Madison, WI, USA), processed in the lab within 48 hours, and stored at -80°C until use. 
Written informed consent was obtained from all subjects who provided stool samples. 
Stool samples were split into two independent sets of noncancerous control subjects and 
colorectal cancer patients. The training set consisted of 66 stool samples from patients 
without colon neoplasia (58 healthy controls, 4 with colonic diverticula and 4 with 
hemorrhoids), 9 stool samples from patients with hyperplastic polyps, 3 stool samples 
from patients with non-advanced adenoma, and 22 stool samples from CRC patients. 
The validation set consisted of 30 control stool samples from healthy individuals, 19 
stool samples from patients with advanced adenoma and 44 stool samples from CRC 
patients (patient characteristics are described in Supplementary Table S7.3). For recovery 
of human DNA, whole stool samples were homogenized in a sevenfold excess volume of 
stool stabilization buffer and aliquoted in 32-mL portions that contained the equivalent 
of 4 g of stool each. DNA isolation was performed as described before.4 Tumor tissue 
DNA of these patients was not available.
Stool sub-samples
Stool sub-samples were obtained from a retrospective collection from referral subjects 
who underwent colonoscopy at the VU University Medical Center in Amsterdam, 
The Netherlands. Stool samples were collected between November 2004 and January 
2007 from referred subjects 1 day before colonoscopy, immediately stored at 4°C and 
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transferred to -20°C at the day of the colonoscopy without stabilization buffer. Stool 
samples from subject subjects with no colon neoplasia (n=48), advanced adenoma (n=24) 
or carcinoma (n=20) were used in this study. Written informed consent was obtained 
from all subjects who provided stool samples. This study was approved by the Medical 
Ethical Committee of the VU University Medical Center. Patient characteristics are 
described in supplementary table 4. At the start of the experiments, stool samples were 
thawed and after performing FIT, ~1 g stool was sampled from each stool sample and 
homogenized in a two-fold excess volume of stool stabilization buffer (Exact Sciences) 
for DNA extraction. DNA was isolated using the QIAamp DNA Stool mini kit (Qiagen, 
Hilden, Germany). Homogenized stool (250 μl) was used as starting material for each 
DNA extraction. DNA was eluted in a volume of 75 μl and DNA from three separate 
isolations from the same sample was pooled.
Sodium Bisulfite conversion and Quantitative Methylation Specific PCR 
(QMSP)
For cell line and tissue DNA, 500 ng was sodium bisulfite-converted using the EZ DNA 
Methylation Kit (Zymo Research, Orange, CA, USA) according to the manufacturer’s 
instructions and eluted in 50 μl Tris/HCL pH8.0. For DNA from whole stool samples, 2 
μg was subjected to bisulfite modification in 96-wells format on a pipetting robot (Tecan), 
using the EZ-96DNA Methylation kit (Zymo Research), according to the manufacturer’s 
protocol and eluted in 30 μl Tris/HCL pH8.0. For DNA from stool subsamples, 2 μg 
of DNA or, when the required volume exceeded the maximum volume according to 
the protocol, a total of 45 μl was subjected to bisulfite modification using the EZ DNA 
methylation kit (Zymo Research) according to the manufacturer’s protocol and eluted in 
25 μl Tris/HCL pH8.0. Conventional MSP was performed on CRC cell lines as described 
before7 with 2 μl bisulfite-modified DNA in a 25 μl volume using 0.5 U of JumpStart Red 
Taq DNA polymerase (Sigma Aldrich, Zwijndrecht, The Netherlands). MSP products 
were analyzed on a 3% agarose gel containing ethidium bromide.
A molecular beacon-based quantitative MSP (QMSP) was developed directed to the 
hypermethylated region of PHACTR3 (+411 to +526 relative to the TSS). QMSP was 
performed on tissue and stool samples was performed on a 7500 fast PCR system and 
7900HT real-time PCR system (Applied Biosystems Foster City, CA) as described 
before,8 with 5 μl of bisulfite-modified DNA per reaction. Tissue samples were analyzed 
in duplicate. Due to their limited amount, stool samples were analyzed in one real-time 
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experiment. A standard curve of a serial dilution of purified PCR product (PHACTR3) or 
plasmid DNA (ACTB) (2x106 – 20) containing the target sequence was used to determine 
the relative quantity of methylation in the unknown samples by interpolating their Ct 
value to the corresponding quantity. Methylation levels in tissues were calculated as 1000 
x (relative quantity of methylated PHACTR3/relative quantity of Beta-actin (ACTB)). In 
stool samples, the relative quantities of PHACTR3 were used as methylation level (no ratio 
was calculated). Only Ct values <40 were included in the calculation. Primer sequences 
are listed in Supplementary Table S7.5.
Reverse transcriptase PCR (RT- PCR)
Total RNA from cell lines was isolated using TRIzol reagent (Invitrogen, Breda, NL), 
and subjected to purification using RNeasy Mini Kit (Qiagen, Venlo, The Netherlands). 
After DNase treatment (RQ1 DNAse, Promega, Leiden, The Netherlands), cDNA was 
made with the Iscript cDNA Synthesis Kit (BioRad, Veenendaal, The Netherlands). 
Quantitative RT-PCR was done using SYBR Green PCR master mix (Applied Biosystems, 
Nieuwerkerk a/d IJssel, NL) as described before,1 with 0.25 μM of each primer and 50 ng 
cDNA. Relative expression levels were determined by calculating the Ct-ratio, using B2M 
as a reference (Ct ratio = 2^-(Ct PHACTR3 – Ct B2M)). Primer sequences are provided 
in Supplementary Table S7.5.
FIT and PHACTR3 methylation analysis in stool sub-samples
FIT’s (OC-sensor®, Eiken Chemical Co., Tokyo, Japan) were processed with the OC sensor 
MICRO desktop analyzer (Eiken Chemical) and analyzed according to the manufacturer’s 
instructions. The commonly used cut-off level of 75 ng/ml was initially used9 to determine 
sensitivity and specificity of FIT without combination with PHACTR3. Because for DNA 
methylation analysis, the stool sub-samples were processed in a different way compared 
to whole stool samples, different cut-offs were used, based on ROC analysis, to determine 
sensitivity and specificity. A cut-off of 0.5 relative copies was used to determine sensitivity 
and specificity of PHACTR3 without combination with FIT. To evaluate whether the 
sensitivity of the combination of FIT and PHACTR3 was significantly higher than the 
sensitivity of either FIT or PHACTR3 methylation alone, we compared the sensitivities 
at equal specificity. To this end, we used a distribution-free rank-based method10 to 
calculate linear combination of the two markers giving highest diagnostic accuracy. The 
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optimal model for the combination of FIT and PHACTR3 methylation was the linear 
combination FIT + 10*PHACTR3 (denoted by Y). Using this model, ROC analysis was 
used to determine the cut-offs at specificities of 92%, 96%, and 98%. At these specificities, 
sensitivities were determined and compared to the sensitivities of PHACTR3 or FIT alone 
using the McNemar’s test.
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Supplementary Figure S7.1 Flowchart for selection of candidate genes. Candidate genes 
were selected using microarray expression analysis of 31 colorectal adenomas and 37 colorectal 
carcinomas, cluster alignment (BROAD analysis) and computational analysis of promoter 
regions (DEEP analysis) and yielded 18 candidate genes (upper part). Further selection was 
made based on experimental evidence of the presence of DNA methylation, which resulted in 
the development of a robust QMSP assay of one candidate gene (lower part).
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Supplementary Figure S7.2 PHACTR3 methylation and mRNA expression analysis in CRC cell 
lines. (A) Schematic illustration of the CpG distribution (vertical lines) around the transcription 
start site (TSS) of PHACTR3 transcript variant 1. MSP primers were designed -149 to -63 bp and 
+411 to +526 bp relative to the TSS. (B) Methylation status in CRC cell lines -149 to -63 bp and 
+411 to +526 bp relative to the TSS, analyzed by MSP. U = unmethylated; M = methylated; 
IvU = unmethylated DNA control IvM = methylated DNA control, H2O = negative water 
control). (C) mRNA expression analysis of PHACTR3 in CRC cell lines by RT-PCR. Quantifications 
represent mean expression values relative to expression in human brain from two independent 
experiments. (D) mRNA expression analysis of PHACTR3 in CRC cells HT29 and HCT116 by RT-
PCR before (-) and after (+) treatment with 1 μM 5-azacytidine. Quantifications represent mean 
expression values (error bars correspond to standard deviation) relative to untreated cells from 
two independent experiments.
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Supplementary Figure S7.2 Continued.
Supplementary Figure S7.3 PHACTR3 DNA methylation levels in different tumor types. 
PHACTR3 methylation levels in carcinomas from brain (glioma, n=20), prostate (n=19), breast 
(n=37), bladder (n=14), lung (n=16), cervix (n=18), pancreas (n=18), gastric (n=14) and 
esophagus (n=7) are shown as (relative quantity of methylated PHACTR3/relative quantity 
of unmethylated Beta-actin (ACTB)) ratio x 1000. Box plots show first quartile, median, third 
quartile and range of methylation levels. Dots represent individual data points, asterisks 
represent extremes.
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Supplementary Figure S7.4 Scatterplot of PHACTR3 methylation levels and FIT values in 
partial stool samples. Scatterplot of PHACTR3 methylation level (y-axis) and FIT values (x-axis) 
for individual samples The horizontal and vertical reference lines represent cut-offs of both 
markers. The left upper quadrant show samples tested positive for PHACTR3 methylation only. 
The right lower quadrant show samples tested positive for FIT only. The right upper quadrant 
show samples tested positive for both PHACTR3 methylation and FIT. Filled circles represent 
stool samples from subjects with CRC (n=20), open circles represent stool samples from subjects 
with advanced adenomas (n=24), crosses represent stool samples from subjects without colon 
neoplasia (n=48).
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Supplementary Table 7.2 Patient characteristics of colon tissue samples
Normal mucosa Advanced adenoma Carcinoma
Number of samples 34 71 64
Age at diagnosis (years ± SD) 66.4 ± 12.9 69.7 ± 11.5 69.2 ± 10.6
Gender
Female 23 33 35
Male 11 38 29
Lesion size (mm)
<10 mm 3
≥10 mm 64 64
Unknown 4
Lesion histological type
Tubular 26
Tubulovillous 37
Villous 6
Unknown 2
Lesion dysplasia
Low-grade 55
High-grade 13
Unknown 3
Lesion diff erentiation
Well 8
Moderate 47
Poor 8
Mucinous 1
Tumor stage
UICC I 21
UICC II 18
UICC III 20
UICC IV 5
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Supplementary Table 7.4 Patient characteristics of partial stool samples
Controls Advanced adenoma Carcinoma
Number of samples 48 24 20
Age at diagnosis (mean [range]) 61.6 [50–77] 66.5 [50–82] 68.3 [58–83]
Gender
Female 25 12 14
Male 23 12 6
Lesion size (mm)
<10 mm 5 0
≥10 mm 19 19
Unknown 0 1
Lesion histological type
Tubular 8
Tubulovillous 14
Villous 1
Unknown 1
Lesion dysplasia
Low-grade 23
High-grade 2
Unknown 1
Tumor stage
UICC 0 24
UICC I 3
UICC II 12
UICC III 3
UICC IV 2
UICC, International Union Against Cancer Classifi cation.
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Supplementary Table 7.5 Primer sequences used for (Q)MSP and RT-PCR
MSP primers
Primer name Sequence (5' to 3’) Location 
relative to 
TSS (bp)
PHACTR3 US 1 TTTATTATGTTGTGTGAGAGGAGTATGATGTTATG -155 to -51
PHACTR3 UAS 1 CACCCCAACACACAATCCAAATATATACA
PHACTR3 MS 1 CGCGAGAGGAGTATGACGTTAC -149 to -63 
PHACTR3 MAS 1 GACGCGCGATCCAAATATATACG
PHACTR3 US 2 GTTATTTTGTGAGTGGTTTTGTGATAT +407 to +527
PHACTR3 UAS 2 ACCTCAAATACTCTAATTCCACACAACT
PHACTR3 MS 2 TTATTTTGCGAGCGGTTTC +411 to +526 
PHACTR3 MAS 2 GAATACTCTAATTCCACGCGACT
PHACTR3 molecular beacon CGACATGCCCGAACCCATAACCGCGTCGAAGCATGTCG +459 to +481
RT-PCR primers
Primer name Sequence (5' to 3’)
PHACTR3 Fw CGCTGGCCACGAAGCA
PHACTR3 Rv GCTTCTTTGGAGACCCTTT
B2M Fw TGACTTTGTCACAGCCCAAGATA
B2M Rv AATGCGGCATCTTCAAACCT
US, unmethylated sense; UAS, unmethylated antisense; MS, methylated sense; MAS, methylated antisense; 
Fw, Forward; Rv, Reverse; TSS, Transcription Start Site; bp, basepair.
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SUMMARY
The first section of this thesis deals with the history of fecal occult blood testing. Screening 
by means of a guaiac based FOBT (g-FOBT) followed by a colonoscopy in case of positivity, 
has been showed to reduce CRC mortality and incidence.1-4 However, g-FOBT has been 
criticized for its fairly low sensitivity and for being non-specific to human hemoglobin. 
Consequently, as an alternative to g-FOBT, a test specific to human hemoglobin was 
sought and the Fecal Immunochemical Test (FIT) was introduced.
In chapter 2 sensitivity and specificity of g-FOBT (Hemoccult-II©) and FIT (OC-sensor©) 
in advanced adenomas and different stages of CRC was assessed in eligible subjects who 
underwent complete colonoscopy. G-FOBT was thereafter considered an unreliable test of 
the past as FIT was found to be more sensitive for CRC and advanced adenomas compared 
to g-FOBT. In a sub analysis of the neoplastic lesions found in the study cohort, sensitivity 
of FIT for the screen relevant neoplasia (SRN) as well as for the early stage cancers and 
advanced adenomas, was proven to be significantly higher compared to g-FOBT. In this 
direct comparison the more current FIT proved to be superior.
Chapters 3 to 6 form the second section of this thesis and concern different strategies 
for the use of FIT for the detection of CRC. One of the major advantages of FIT is the 
non-dichotomous outcome. By adjusting the cut-off value, the test positivity rate can be 
influenced. The influence of using higher cut-off values for a FIT on the detection rates 
of SRN was assessed in chapter 3. It was found that higher FIT cut-off levels substantially 
decrease test positivity rates with only limited effects on detection rates of early-stage 
CRCs. Adjusting the threshold for positivity of quantitative fecal immunochemical tests 
(FIT) will allow for controlling the number of initial colonoscopies in a screening program.
Chapter 4 focuses on repeated FIT sampling as another strategy, aimed at improving 
test sensitivity of FIT for detection of early stage CRC and its precursors, defined as 
SRN. Test positivity and sensitivity of double FIT sampling was evaluated for three 
different strategies at several cut-off values, “one of two FITs positive” when at least one 
out of two measurements exceeded the cut-off value, 2) “both FITs positive” when both 
measurements exceeded the cut-off value, and 3) “the average of two FITs positive” when 
the geometric mean of two FITs exceeded the cut-off value. Regardless of the cut-off that 
was used, “two of two FITs+” resulted in the lowest and “one of two FITs+” in the highest 
sensitivity for SRN (range 35–44% and 42%–54% respectively). Receiver Operator Curves 
(ROCs ) of double FIT sampling were similar to those of single FIT sampling. However, 
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at fixed levels of specificity of 85/90/95%, sensitivity of any double FIT sampling strategy 
did not significantly differ from single FIT (p-values 0.07–1.00). In conclusion, none of 
the double FIT strategies had a superior combination of sensitivity and specificity over 
single FIT.
In chapter 5 the focus lies on false positive FITs. In a screening setting, false positive 
results will result in futile colonoscopies. In this chapter, the contribution of hemorrhoids 
on the frequency of false positive FITs was determined. In only 9 individuals, out of a 
cohort of 2855 patients, who had a FP FIT (4.1%; 95% CI 1.4–6.8), hemorrhoids were the 
only abnormality found. In univariate unadjusted analysis, subjects with hemorrhoids 
as single abnormality did not have more positive results (9/134; 6.7%) compared with 
subjects without any abnormalities (43/886; 4.9%; p=0.396). Logistic regression identified 
hemorrhoids, non advanced polyps and a group of miscellaneous abnormalities(for 
instance angioectasia) all of significantly influence on false positivity. Still, hemorrhoids 
detected at colonoscopy remain an infrequent cause of false positive fecal immunochemical 
tests and therefore, the influence of hemorrhoids on the effectiveness of an FIT-based 
screening program is likely to be limited.
Recently, FITs were found to have a higher sensitivity and lower specificity for advanced 
colorectal neoplasia in males compared to females. The aim of chapter 6 is to compare 
males and females with respect to the sensitivity and specificity of FIT, at different cut-off 
values. Outcomes were CRC and advanced adenomas. We studied whether location in the 
large bowel, number and size of neoplastic lesions were potential explanatory variables 
in the relation between sex and FIT characteristics. 
Using cut-off values between 50–100 ng/ml, a large but non-significant difference of 13%, 
was found for sensitivity for CRC in favor of men. FIT was significantly more specific for 
CRC in females than in males. By choosing a lower cut-off value for women, corresponding 
test characteristics could be reached. For advanced adenomas no sex-specific differences 
of any clinical relevance were observed. Additionally, FIT proved to be more sensitive 
for left-sided lesions than for right-sided lesions. However, a difference in distribution of 
lesions between the sexes proved to not be responsible for the observed gender disparities. 
Gender specific screening guidelines could be considered in order to optimize or balance 
the effectiveness of a screening program in males and females. However, since sensitivity 
for advanced adenomas did not differ between men and women and compliance to 
screening programs is known to be higher in women, the observed gender difference 
will probably hold no consequences for the design of a screening program.
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Occult gastrointestinal blood loss is unspecific to colonic cancers and large adenomas, 
while there are several other possible causes.5 Blood loss from other sources like, for 
instance, colonic angioectasia will lead to false positive FIT results. Furthermore, false 
negative results can occur because blood loss from neoplastic lesions is intermittent.6 
False negative FIT’s can be a serious problem for the credibility of nationwide screening 
program. In chapter 7 the combination of FIT with a methylation marker, in order 
to improve the FIT for future use, is assessed. Phosphatase and Actin Regulator 3 
(PHACTR3) was identified from a pool of potential candidates using a bio-informatics 
based strategy, as a novel hypermethylated gene that could serve as a biomarker for 
early detection of colorectal cancer in stool. Subsequently, the complementary value to 
a Fecal Immunochemical Test (FIT) was evaluated in two series of whole stool samples, 
which were specifically collected for this purpose. It was found that adding PHACTR3 
methylation to FIT increased its sensitivity for CRC up to 15%. This new hypermethylated 
gene in CRC has a good performance in stool DNA testing and was found to have a 
additional value to FIT.
GENERAL DISCUSSION AND FUTURE PERSPECTIVES
Prevention of colorectal cancer (CRC) is the ultimate goal of CRC screening. In order to 
achieve the maximum benefit in terms of reducing morbidity and mortality, a primary 
CRC screening tool must be able to effectively detect advanced precursor lesions and 
cancers at a curable stage throughout the colon. 
In September 2013, the much anticipated national screening program for CRC in the 
Netherlands will finally be initiated.7 Adequate knowledge on test performance of the 
primary screening tool is crucial for making estimations of the logistic demands for such 
a program and is therefore essential for projecting the needed capacity to meet the needs 
for a nationwide screening program. 
Nationwide screening programs are well on their way in several (other) countries. At the 
time of the initiation of the research reported in this thesis, g-FOBT was the test most 
used in screening programs. At present, g-FOBT is being replaced by FIT. 
The research described in this thesis focuses on the diagnostic accuracy of FITs. Studies 
of diagnostic test accuracy require the true disease status of each individual to be known. 
In our population this was determined by colonoscopy, which was considered the gold 
standard. Here, sensitivity and specificity were calculated in a large cohort of individuals 
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who were referred for colonoscopy. To avoid bias this gold standard was conducted and 
interpreted while the endoscopists were blinded to the FIT result. 
A limitation of our FIT-cohort is that it is a referral population, partially containing high 
risk individuals, rather than a true screening population. In a referral population the 
prevalence of CRC is higher when compared to a true screening population, which consist 
of asymptomatic individuals. Therefore, test characteristics that depend on the prevalence 
of disease, like the positive and negative predictive values, could not be generalized 
from this population. Sensitivity and specificity however, are test characteristics not 
influenced by the prevalence of the disease.8 Yet due to work-up bias, in this cohort 
of referred individuals, sensitivity could still have been overestimated and specificity 
underestimated.9 Work-up bias can influence results, as a subset of the individuals has 
signs or symptoms which increase the likelihood of having both a positive FIT and CRC.9 
Nevertheless, it can be questioned whether a screening population could indeed be free 
of work-up bias, as it was previously shown that almost half of the subjects with screen 
detected CRC experienced hematochezia.10 Similar results are found when comparing 
sensitivity and specificity of the FIT described in this thesis with results of some of the 
large screening trials using a FIT.11,12
Identifying the most suitable FIT for a screening program and, consequently, reaching the 
maximum benefit from FIT screening, requires comparability of results between different 
FITs. FITs new on the market should be evaluated properly and should be compared to 
the current standard.13 In order to facilitate adequate comparison of FITs in the future, 
the concentrations of hemoglobin that one FIT measures should be comparable with the 
result of a FIT from another manufacturer. For this purpose, uniformity in reporting is 
required. This analytical comparability could be reached by expressing the quantity of 
hemoglobin present in the amount of feces in the FIT tube and not in the amount of 
buffer solution in the test tube.14
Compliance to screening and accuracy of the screening tests are the two major 
determinants of the effectiveness of a screening program.15,16 With compliance rates 
around 50%, participation remains poor in population screening programs carried out 
in Europe. Criticizing the test to be used in a screening program could bear the risk of 
undermining the faith the general public has in the test and thereby reduce adherence, 
even before the initiation of the Dutch population screening program. The current debate 
among professionals concerning the preferred FIT for screening could therefore lead to 
a reduced uptake of CRC screening.
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To date, the Fecal Immunochemical Test seems to be the best available primary screening 
test for CRC screening as it meets some of the major requirements: it can detect both 
advanced adenomas and early cancers, it has high specificity to keep the costs of screening 
low and minimize risks to healthy patients, and it is user-friendly, affordable, and widely 
available.17
FUTURE PERSPECTIVES
Knowledge on test performance and acceptance is required for selection of the FIT best 
suited to meet pre-specified clinical and logistical requirements of a screening program. 
FITs detect blood in stool. Occult blood loss in the colon is non-specific to neoplastic 
disease and consequently hemoglobin is not an ideal marker for the presence of colonic 
adenomas and cancers. Additionally, it is unknown whether the adenomas most likely to 
bleed are indeed those adenomas most likely to progress to malignant disease. As a result, 
FIT is a rather unspecific tool for detecting (pre)cancerous colonic lesions. Therefore, 
although it seems to be the best available option at this moment, FIT might not maintain 
this status in the future.
In order to improve the uptake of a CRC screening program, markers specifically targeted 
at those adenomatous lesions most likely to progress are needed. These markers could 
be tumor derived DNA products in stool. However, the ultimate panel of markers for a 
stool DNA test still has to be developed.18
In the Netherlands, the upcoming screening program will create the opportunity to 
assess the new FITs and other stool markers and compare them to the current standard. 
This will hopefully facilitate translation of basic research into screening tools ready for 
implementation into screening programs. 
This thesis touched on the past and present use of FITs in CRC screening. As new options 
will arise in the upcoming years, FIT will probably not hold up as a single marker test 
in screening programs. The question therefore remains for how long the “FI-test” will 
survive?
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Samenvatting
Dit proefschrift heeft als onderwerp de testkarakteristieken van fecaal occult bloed tes-
ten (FOBT’s), voor de detectie van het colorectaal carcinoom (CRC) en zijn voorloper 
laesies, de adenomen. De FOBT’s detecteren bloed in de ontlasting, dat vanuit deze 
neoplastische laesies wordt verloren. Een positieve uitslag van de FIT wordt dan gevolgd 
door een colonoscopie, waarbij een diagnose gesteld kan worden. De nieuwe generatie 
FOBT’s, die Fecale Immunochemische Test (FIT) wordt genoemd, zal vanaf januari 2014 
in Nederland worden gebruikt in het bevolkingsonderzoek darmkanker.  
In de verschillende delen van het proefschrift wordt achtereenvolgens de FIT vergeleken 
met de FOBT uit het verleden, wordt gekeken naar verschillende aspecten van het actuele 
gebruik van de FIT en wordt tot slot gekeken naar een potentiële verbetering van de test 
voor toekomstig gebruik.
In het eerste deel van het proefschrift wordt de FIT vergeleken met de zogenaamde guaijak 
FOBT (g-FOBT). Van het gebruik van de g-FOBT als screeningtest in een bevolkingson-
derzoek op darmkanker is bekend dat het de mortaliteit en de incidentie van CRC kan 
reduceren. Echter, de g-FOBT is berucht vanwege zijn lage sensitiviteit en specificiteit. In 
hoofdstuk 2 wordt de sensitiviteit en specificiteit van g-FOBT (Hemoccult-II©) en FIT 
(OC-sensor©) berekend voor de gevorderde adenomen en de verschillende stadia van 
CRC. Dit werd gedaan door studiedeelnemers beide testen simultaan te laten uitvoeren. Zij 
ondergingen vervolgens een volledige colonoscopie, waarbij eventuele CRC of adenomen 
werden gekoppeld aan uitslagen van de beide testen. De FIT bleek overtuigend sensitiever 
voor CRC en gevorderde adenomen dan de g-FOBT. In een subanalyse waarbij vroege 
carcinomen en gevorderde adenomen tezamen werden genomen (de voor screening 
relevante neoplasia of SRNs genaamd), bleek de sensitiviteit van de FIT voor deze groep 
significant hoger te zijn dan de sensitiviteit van de g-FOBT. 
De hoofdstukken 3 tot en met 6 vormen het tweede deel van dit proefschrift en beschrijven 
de verschillende strategieën met betrekking tot het actueel gebruik van de FIT voor het 
opsporen van CRC en zijn voorlopers.
Eén van de grote voordelen van de FIT is dat het een kwantitatieve test is, waarbij een 
afkapwaarde wordt ingesteld boven welke de test positief wordt genoemd. Door de 
afkapwaarde aan te passen kan het percentage positieve uitslagen beïnvloed worden. 
Uiteindelijk zal dit bij het bevolkingsonderzoek relevant zijn voor het aantal verwij-
zingen voor colonoscopie. Een hogere afkapwaarde zal leiden tot minder verwijzingen 
voor colonoscopie en is daarmee zeer relevant voor de planning van de logistiek van een 
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bevolkingsonderzoek. De invloed van het gebruik van hogere afkapwaarden voor de FIT 
op de detectie van CRC en gevorderde adenomen wordt geëvalueerd in hoofdstuk 3. 
Bij het gebruik van hogere FIT-afkapwaarden bleek dat het percentage gevonden vroeg-
carcinomen nagenoeg gelijk bleef. 
Hoofdstuk 4 is toegespitst op het uitvoeren van niet één maar twee FIT’s, teneinde de 
sensitiviteit en specificiteit van de test voor CRC en zijn voorlopers te verbeteren. De 
positiviteitsgraad (het percentage testen met positieve uitslag) en sensitiviteit van een 
dubbele FIT-afname werd geëvalueerd voor drie verschillende strategieën bij verschillende 
afkapwaarden: 1) “Tenminste 1 van de 2 FIT’s positief ” wanneer ten minste één van de 
uitslagen de afkapwaarde overschreed, en 2) “beide FIT’s positief ” wanneer de uitslagen 
van beide testen de afkapwaarde overschreden en 3) ”het gemiddelde van 2 positieve 
FIT’s” wanneer het meetkundig gemiddelde van de twee FIT’s de afkapwaarde over-
schreed. Ongeacht de gebruikte afkapwaarde leidde “beide FIT’s positief ” tot de laagste 
en “Tenminste 1 van de 2 FIT’s positief ” tot de hoogste sensitiviteit voor SRN, met een 
respectievelijke spreiding van 35–44% en 42–54% . ROC-curves (Receiver Operator Cha-
racteristic curves) van het uitvoeren van twee FIT’s waren gelijk aan die van het uitvoeren 
van een enkele FIT. Echter, bij vaststaande niveaus van specificiteit (85%/90%/95%) bleek 
de sensitiviteit van dubbele FIT-afname niet significant te verschillen van een enkele FIT-
afname (p-waardes 0.07–1). Concluderend blijkt geen van de herhaalde FIT-strategieën 
een duidelijke meerwaarde te hebben wat betreft sensitiviteit en specificiteit. 
In hoofdstuk 5 ligt het zwaartepunt op foutpositieve FIT-uitslagen. Binnen het kader 
van een bevolkingsonderzoek leiden foutpositieve FIT’s tot onnodig uitgevoerde co-
lonoscopieën. Bloedverlies uit andere bronnen dan CRC en gevorderde adenomen zal 
immers ook tot een positieve FIT leiden. Hemorroïden zijn een beruchte oorzaak van 
rectaal bloedverlies. In dit hoofdstuk wordt het aandeel van hemorroïden in het totaal 
van foutpositieve FIT-uitslagen bepaald. In een cohort van 2855 patiënten vormden 
hemorroïden bij slechts 9 individuen de enige bij coloscopie gevonden afwijking. In 
een univariate analyse hadden personen met hemorroïden als enige afwijking niet meer 
positieve uitslagen (9/134; 6.7%) dan personen waarbij geen enkele afwijking werd ge-
vonden bij colonoscopie (43/886; 49%; p=0.396). Logistische regressieanalyse toonde 
aan dat hemorroïden, ”non-advanced” poliepen en een groep van diverse afwijkingen 
(zoals intestinale angiodysplasieën) de foutpositiviteit van FIT allen significant beïn-
vloeden. Desondanks blijven hemorroïden een zeldzame oorzaak van een foutpositieve 
immunochemische feces occult bloed test en is de invloed van hemorroïden op de ef-
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fectiviteit van een FIT bij het gebruik in een bevolkingsonderzoek op CRC waarschijnlijk 
beperkt.
Uit een eerdere publicatie is gebleken, dat FIT’s een hogere sensitiviteit en een lagere 
specificiteit voor CRC en gevorderde adenomen hebben bij het gebruik door mannen in 
vergelijking tot het gebruik door vrouwen. Het doel van hoofdstuk 6 was het vergelijken 
van sensitiviteit en specificiteit van FIT voor CRC en gevorderde adenomen bij gebruik 
door mannen en door vrouwen. Onderzocht werd of locatie in de dikke darm, het aantal 
en de grootte van de gevonden neoplastische laesies potentieel verklarende variabelen 
zijn in de relatie tussen geslacht en FIT-kenmerken. 
Door afkapwaarden tussen 50–100 ng/ml te gebruiken werd een aanzienlijk, doch niet 
significant, verschil van 13% gevonden voor CRC ten gunste van mannen. Door een lagere 
afkapwaarde voor vrouwen te kiezen, zouden overeenkomende testkenmerken bereikt 
kunnen worden. Voor de gevorderde adenomen werden geen klinisch relevante verschillen 
tussen de seksen gevonden. Tevens bleek FIT sensitiever voor laesies gelokaliseerd in het 
linker hemicolon dan voor laesies die zich aan de rechterkant van het colon bevonden. 
Een verschil in distributie van de laesies over het colon bleek echter niet verantwoordelijk 
voor de gevonden sekseverschillen. Tot slot bleek FIT significant specifieker voor CRC 
bij het gebruik door vrouwen in vergelijking met gebruik door mannen. Seksespecifieke 
richtlijnen voor het bevolkingsonderzoek zouden overwogen kunnen worden teneinde 
de effectiviteit van het programma voor mannen en vrouwen te optimaliseren. Echter, 
gezien het feit dat de sensitiviteit voor gevorderde adenomen niet verschilt voor man-
nen en vrouwen en omdat de compliantie aan screeningsprogramma’s onder vrouwen 
aanzienlijker hoger ligt, zal het geobserveerde sekseverschil hoogstwaarschijnlijk geen 
consequenties hebben voor het ontwerp van een bevolkingsonderzoek. 
Occult gastro-intestinaal bloedverlies is niet specifiek voor CRC en gevorderde adenomen. 
Er zijn meerdere oorzaken voor intestinaal bloedverlies, zoals bijvoorbeeld de eerder 
genoemde intestinale angiodysplasieën. Derhalve kan een test die bloed als biomarker 
neemt per definitie slechts beperkt specifiek zijn. 
Naast fout-positief kan een FIT ook fout-negatief zijn. In een dergelijk geval is een neoplas-
tische laesie in het colon aanwezig maar is de FIT negatief. Fout-negatieve FIT’s kunnen 
een groot probleem vormen voor de geloofwaardigheid van een bevolkingsonderzoek. 
Hoofdstuk 7 onderzoekt of de toevoeging van een zogenaamde methyleringsmarker aan 
de test, de FIT voor toekomstig gebruik kan optimaliseren. 
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Gebruikmakend van een strategie uit de bio-informatica werd een nieuw hypergemethy-
leerd gen in CRC geïdentificeerd, genaamd Fosfatase Actine Regulator 3 (PHACTR3). 
PHACTR3 kan dienen als biomarker voor de vroege detectie van darmkanker in ont-
lasting. De potentiële additionele waarde van de PHACTR3 marker aan een FIT werd 
geëvalueerd in twee series van ontlastingmonsters die specifiek voor dit doel waren 
verzameld. Vastgesteld werd dat de sensitiviteit van FIT voor CRC tot wel 15% toenam 
door het toevoegen van de PHACTR3 marker. Deze marker heeft dus veel potentie en 
lijkt van toegevoegde waarde te zijn bij het gebruik van FIT. 
De titel van dit proefschrift luidt: “De overleving van de Fecaal Immunochemische Test”. 
Het beschrijft een vergelijking van FIT met de FOBT uit het verleden en daarnaast verschil-
lende aspecten aangaande het huidige gebruik van de FIT in de context van de screening 
op CRC. Op dit moment lijkt de FIT de best beschikbare test te zijn voor een bevolkings-
onderzoek naar CRC. Echter, gezien de snelheid waarmee nieuwe biomarkers worden 
ontwikkeld blijft de vraag hoe lang de FIT in zijn huidige vorm zal worden gebruikt.
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Promoveren is een kwestie van heel veel rijst eten (met name ook in tijden dat je geen trek 
hebt in rijst) met eens in de zoveel tijd een krent op de lepel. En al zijn ze soms weinig 
prevalent, de krenten geven aanleiding tot mooie momenten en herinneringen. Het eten 
van rijst en krenten heeft uiteindelijk geleid tot de totstandkoming van dit proefschrift. 
In dit dankwoord wil ik iedereen bedanken die daar aan heeft bijgedragen. Ik hoop 
overigens dat ik mij in de afgelopen jaren zodanig heb opgesteld dat iedereen met wie ik 
samen heb gewerkt, mijn waardering al eerder gevoeld heeft. 
Allereerst mijn promotores Prof. Dr. C.J.J. Mulder en Prof. Dr. G.A. Meijer. Beide heren 
wil ik danken voor de kans die ik kreeg om aan dit promotietraject te beginnen. 
Beste Chris, de tomeloze energie die jij hebt, werkt aanstekelijk. Tijdens mijn onderzoeks-
periode gaf je me elke keer de ruimte en het vertrouwen voor het regelen van wéér een 
volgende logistieke uitdaging. Door het vertrouwen heb ik me een enkele keer ongemak-
kelijk gevoeld, bijvoorbeeld als enige “onder-onder-knuppel” bij een “bovenknuppel-
overleg”, maar achteraf bleek het altijd weer een leerzame ervaring te zijn geweest. Ook het 
bezoeken van congressen was en is altijd een genoegen in jouw aanwezigheid. Ik herinner 
me een gezamenlijke vlucht van New York naar Chicago gevuld met het doorspreken van 
de laatste stand van zaken betreffende mijn proefschrift, nieuwe ideeën voor onderzoek, 
naast uiteraard een verhandeling over het vervangen van een motor in een VW Passat 
en over het type boormachine dat ik thuis in de kast heb liggen.  
Beste Gerrit, door de wekelijkse TP-meeting met de Tumor Profiling groep had ik direct 
vanaf het begin het gevoel dat het onderzoek in het CCA en wat er zich op de MDL-afdeling 
afspeelde sterk verweven was. Jouw hoge mate van organisatie en efficiëntie, altijd geholpen 
met het nieuwste wat de ICT-wereld te bieden heeft, zijn een voorbeeld en garandeerden 
het gevoel van jouw betrokkenheid bij wat ik deed. Een email met een voor mij belangrijke 
vraag, werd ook in tijden van een steeds drukker wordende agenda, vlot beantwoord. Het 
jaarlijkse Hattem-event in jouw achtertuin en andere uitjes versterkten het teamgevoel 
tussen MDL en PA en hebben geresulteerd in contacten die niet zullen verwateren.
Mijn co-promotor, Dr. R.W.M. van der Hulst, beste René, jij was van groot belang voor 
de voortgang en de uiteindelijke totstandkoming van dit proefschrift. Je functioneerde 
als sparringpartner, had altijd een kritische blik op abstracts en manuscripten en bovenal 
hield je de druk op de ketel. Druk op de ketel, zo leert mijn ervaring, is essentieel voor 
het afmaken van een promotietraject tijdens een MDL-specialisatie. Ik ben blij om te 
zien dat de FIT-studies jou ook mooie dingen hebben gebracht. 
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Mijn paranimfen Bart Verwer en Tim Schreuder. Dank voor de collegialiteit, vriendschap 
en gezelligheid door de jaren heen. Het contact wisselt sinds 2009 altijd in intensiteit, 
maar zal altijd blijven bestaan. Ik ben blij dat jullie, na de generale repetitie van december 
2012 (!), nu naast mij op het podium staan. 
De Romeinse 2 aan de zijkant van dit boek is de ultieme uiting dat promoveren een team-
prestatie is. Zoals ook naar voren komt uit de verschillende auteurslijsten in dit boek, zijn 
de publicaties van de CRC-onderzoekers van de MDL-afdeling van het VUmc dermate 
arbeidsintensief en langjarig georganiseerd dat dit zonder het werk van een team nooit 
tot stand was gekomen. Voorganger Jochim (‘de Romeinse 1’) en opvolgers Sietze en 
Ilhame ontzettend bedankt voor de prettige en succesvolle samenwerking, die hopelijk 
nog lang zal voortduren. Ilhame ook dank voor de inspiratie tot de titel van dit boek.
De leden van mijn leescommissie, mw. Dr. E. Dekker, Dr. R.J.A. Fijneman, mw. Dr. 
N.C.T. van Grieken, Prof. Dr. J.B.M.J. Jansen, mw. Dr. M.E. Van Leerdam en Prof. Dr. 
A.A.M. Masclee wil ik graag danken voor de tijd en aandacht die ze aan het lezen van 
dit proefschrift hebben besteed.
Dank aan alle medewerkers, artsen, verpleegkundigen en andere medewerkers van de 
endoscopie-afdelingen van de participerende ziekenhuizen in de GUT-club ziekenhuizen, 
te weten het Kennemer Gasthuis, het Slotervaart Ziekenhuis, het Zaans Medisch Cen-
trum, het VU medisch centrum en( last but certainly not least) het Sint Lucas Andreas 
Ziekenhuis. Met name wil ik ook de lokale coördinatoren in genoemde ziekenhuizen 
noemen; mw. Drs. A.C.T.M. Depla, Dr. R.J.L.F Loffeld, Drs. P. Scholten en uiteraard mijn 
co-promotor. Zonder de inspanningen van de medewerkers van genoemde afdelingen, 
was dit onderzoek nooit tot stand gekomen. 
Collega’s van de afdeling klinische chemie van het VU medisch centrum, Prof. Dr. M.A. 
Blankenstein en mw. Dr. A.A. Bouman en uiteraard projectanalyst Edwin van Hengel 
hartelijk dank voor de vruchtbare samenwerking. Edwin, dank voor de grote inzet die je 
al die jaren hebt geleverd en nog steeds levert voor de FIT-studies.  
Alle meewerkende studenten; Liesbeth Mutsaers, Laura de Baay, Roy van Wanrooy, 
Suzanne van de Reijt, Maarten Neerincx, Mirre Räkers, Ilhame Ben Larbi, Shannon Kanis, 
Madelon Wentink, Ruud Duijkers, Zaldy Valdehueza en Rosalie Ooteman. Met z’n allen 
(en uiteraard ook iedereen die nog na jullie is gekomen) hebben we er toch maar een 
mooie poep-verzameling van gemaakt. 
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Mede-ondezoekers Wieke, Bart, Bindia, Maria, Jolanda, Greetje, Tze, Dirk en Thijs. 
Mooi om door de jaren heen zoveel met elkaar op trekken en elkaars pres(en)taties op 
de verschillende congressen te zien (…excellent talk, as always!…).
Mijn dank gaat ook uit naar de leden van de Tumor Profiling Unit van de afdeling Patho-
logie van het VU medisch centrum waar ik het meest mee te maken heb gehad, te weten 
Linda, Sandra, Beatriz, Remond, Rinus, Meike, Tineke, Cindy en Bego. Dank voor alle 
ondersteuning en prettige samenwerking.
Dankzij Dr. N.A.M. van Ooteghem en Dr. I.C.E. Wesdorp ben ik tijdens een wetenschaps-
stage in het SLAZ enthousiast geraakt voor het vak van MDL-arts. Ik wil Nancy en Eric 
danken voor hun support richting de promotieplek in het VUmc. De bijnaam die ik op 
de endoscopie-afdeling van het SLAZ tijdens deze onderzoeksstage naar feacale markers 
op Helicobacter pylori kreeg, greep alleen maar meer om zich heen door de aard van 
mijn promotie-onderzoek. Het kostte ongeveer 400 scopieën tijdens mijn opleiding op 
dezelfde afdeling, voordat ik niet meer dagelijks met deze bijnaam geconfronteerd werd…
Dr. D.P. Bezemer, Dr. J. Berkhof en vooral ook mw. Dr. V.H.M. (Veerle) Coupé van de 
Afdeling epidemiologie & biostatistiek van het VU medisch centrum bedankt voor de 
ondersteuning bij de statistiek.
Dames van de polikliniek en het secretariaat MDL, dank voor de ondersteuning in de 
afrondende fase van dit proefschrift. Jessica dank voor controle nakijken van het Engels.
SLAZ-collega Marcel Schouten voor het faciliteren van toegang tot de eindeloze lijst van 
internationale wetenschappelijke tijdschriften. Opvallend wat alleen een, over de jaren 
wisselend, wachtwoord al over iemand kan vertellen…
Bart Ferket, dank voor de intensieve samenwerking aan het, wat ik denk eerste, vrijwel 
landelijk uitgerolde BVO voor CRC in Nederland. Buiten onze macht om bleef er helaas 
maar rijst op tafel verschijnen en bleven de krenten uit. In een andere tak van sport heb 
jij inmiddels ook je promotie gepland staan. 
Alle (schoon)familie en vrienden; dank voor de steun en met name ook het begrip als er 
weer wat tijd achter een computer doorgebracht moest worden. 
Mijn ouders, dank voor het vertrouwen en alle steun die jullie mij hebben gegeven. Het 
staat als een paal boven water dat ik zonder jullie nooit tot dit punt was gekomen! 
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Uiteraard als laatste genoemd, maar mijn allergrootste dank gaat uit naar Tanja, mijn steun 
en toeverlaat. Dank voor de ruimte die je me de afgelopen jaren gaf om dit project af te 
ronden. Ik besef me dat jij en Thijs met name getuige zijn geweest van het “rijst eten” en 
dat er een hoop saaie(danwel krentenloze) weekenden zijn gepasseerd voor jullie. Cleo, 
dankjewel dat je me een duidelijke deadline gaf om de werkkamer te ontruimen. Ik ben 
blij dat ik het gehaald heb.
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CURRICULUM VITAE 
Frank Albert Oort werd op 30 juni 1979 geboren te Heemskerk. Hij behaalde in 1997 
zijn atheneumdiploma aan het Jac. P. Thijsse College te Castricum. Vervolgens startte 
hij zijn studie geneeskunde aan de Vrije Universiteit te Amsterdam, waar hij in 1998 zijn 
propedeuse behaalde. Tijdens zijn studie werkte hij onder meer als webredacteur voor 
verschillende medische websites en als practicumbegeleider bij de vakgroep Klinische 
Chemie van de medische faculteit van de Vrije Universiteit. 
Door een onderzoeksstage bij de afdeling Maag-, darm- en leverziekten van het Sint Lucas 
Andreas Ziekenhuis (begeleiders Dr. N.A.M. van Ooteghem en Dr. I.C.E. Wesdorp), waar-
voor hij zijn co-schappen in 2005 onderbrak, raakte zijn interesse in de gastroenterologie 
gewekt. Met een oudste co-schap bij de afdeling Maag-, Darm- en Leverziekten van het 
Medisch Centrum Alkmaar, rondde hij zijn opleiding tot arts af. Na het behalen van het 
artsenbul deed hij klinische ervaring op als assistent-geneeskundige niet in opleiding 
(AGNIO) op de afdelingen Interne Geneeskunde, Cardiologie en Longziekten van het 
Kennemer Gasthuis te Haarlem (opleider Prof. Dr. R.W. ten Kate).  
In maart 2007 startte hij met promotieonderzoek naar de testkarakteristieken van scree-
ningstesten die in het aanstaande bevolkingsonderzoek darmkanker gebruikt zullen 
worden, onder begeleiding van promotoren Prof. Dr. C.J.J. Mulder, Prof. Dr. G.A. Meijer 
en co-promotor Dr. R.W.M. van der Hulst. Na een voltijds onderzoeksperiode van 2 jaar 
startte hij met de vooropleiding Interne Geneeskunde in het Sint Lucas Andreas Zieken-
huis (opleider Dr. C.E.H. Siegert). In hetzelfde ziekenhuis vervolgde hij zijn opleiding tot 
maag-, darm- en leverarts (opleider Drs. P. Scholten). Vanaf mei 2012 is hij werkzaam 
als maag-, darm- en leverarts in opleiding in het VU medisch centrum te Amsterdam 
(opleider Dr. R.A. de Vries). Begin 2015 zal hij zijn opleiding afronden.
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